var title_f13_23_13680="Control of liver bleeding using the Pringle maneuver";
var content_f13_23_13680=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F51354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F51354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Control of liver bleeding using the Pringle maneuver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 414px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Control of bleeding from the injured liver can be accomplished by occluding arterial and portal venous flow into the liver with manual compression or using a vascular clamp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_23_13680=[""].join("\n");
var outline_f13_23_13680=null;
var title_f13_23_13681="Anatomic landmarks for emergency cricothyrotomy";
var content_f13_23_13681=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Anatomic landmarks for emergency cricothyrotomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Understanding of the local anatomy is critical to the performance of cricothyrotomy. The laryngeal prominence forms the superior edge of the thyroid cartilage, where there&nbsp;is often a prominent, palpable&nbsp;&ldquo;V-shaped&rdquo; notch. The vocal cords are housed within and protected by the thyroid cartilage. The hyoid bone lies cephalad to the thyroid cartilage and in patients where the thyroid cartilage is not prominent&nbsp;it&nbsp;can be mistaken for the thyroid prominence. The cricoid cartilage is a complete cartilaginous ring located caudal to the thyroid cartilage. The cricothyroid membrane lies between the thyroid and cricoid cartiages.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_23_13681=[""].join("\n");
var outline_f13_23_13681=null;
var title_f13_23_13682="Infraclavicular brachial plexus block";
var content_f13_23_13682=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Infraclavicular brachial plexus block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 507px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient is placed in the supine position with the head turned away from the side of the block. The arm is abducted with the elbow flexed to identify the coracoid process. In a location two centimeters medial and two centimeters caudad to the tip of the coracoid process, the needle is inserted vertically (red dot). With demonstration of the appropriate muscle twitches or sonographic needle placement, local anesthetic is administered.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_23_13682=[""].join("\n");
var outline_f13_23_13682=null;
var title_f13_23_13683="Vaccinia virion on EM";
var content_f13_23_13683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Poxvirus virions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 210px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph shows intracellular brick-shaped vaccinia virions with dense central core and outer viral membranes (blue arrows). The electron microscopic image of variola virus would be identical to that seen here with vaccinia virus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Herrera E, del mar Lorenzo M, Blasco R, Isaacs SN. J Virol 1998; 72:294.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_23_13683=[""].join("\n");
var outline_f13_23_13683=null;
var title_f13_23_13684="Vaginal anterior repair";
var content_f13_23_13684=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69730&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69730&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Transvaginal anterior repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 614px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anterior colporraphy - With the patient in the dorsal lithotomy position, the anterior vaginal wall is clearly visualized. Using allis clamps to grasp the anterior vaginal wall, a transverse incision is made using a knife at the proximal aspect of the defect. Sharp dissection in a vertical manner is then performed as superficial as possible using Metzenbaum scissors along the midline of the anterior vaginal wall, staying at least 1 cm away from the external urethral orfice (Image A). Sharp dissection is performed bilaterally to clear the mucosa from the underlying muscularis and adventitia to the level of the pubic symphysis (Image B). Plication of the remaining muscularis and adventitia is then performed with a delayed absorbable suture, thereby repairing the anterior wall support defect (Image C). The vaginal muscosa is then trimmed and closed in a running manner.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_23_13684=[""].join("\n");
var outline_f13_23_13684=null;
var title_f13_23_13685="Echinococcal liver cyst CT";
var content_f13_23_13685=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Echinococcal cyst of the liver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A computed tomogram shows a multilocular cyst in the liver of a patient with hydatid disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sun T. Parasitic Disorders: Pathology, Diagnosis, and Management, 2nd edition. Baltimore: Lippincott Williams &amp; Wilkins, 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_23_13685=[""].join("\n");
var outline_f13_23_13685=null;
var title_f13_23_13686="Phenylephrine (systemic): Pediatric drug information";
var content_f13_23_13686=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Phenylephrine (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?6/47/6903?source=see_link\">",
"    see \"Phenylephrine (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/59/33717?source=see_link\">",
"    see \"Phenylephrine (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9504748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9504766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Medi-First&reg; Sinus Decongestant [OTC];",
"     </li>",
"     <li>",
"      Medi-Phenyl [OTC];",
"     </li>",
"     <li>",
"      PediaCare&reg; Children's Decongestant [OTC];",
"     </li>",
"     <li>",
"      Sudafed PE&reg; Children's [OTC];",
"     </li>",
"     <li>",
"      Sudafed PE&reg; Congestion [OTC];",
"     </li>",
"     <li>",
"      Sudafed PE&trade; Nasal Decongestant [OTC];",
"     </li>",
"     <li>",
"      Sudogest&trade; PE [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10514172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenergic Agonist Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Alpha-Adrenergic Agonist",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sympathomimetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12808756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypotension/shock: Continuous I.V. infusion: 0.1-0.5 mcg/kg/minute, titrate to desired effect",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10514284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/47/6903?source=see_link\">",
"      see \"Phenylephrine (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nasal decongestant: Oral: Manufacturer's recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Phenylephrine hydrochloride salt:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children's Sudafed PE&reg;: Children 4-5 years: 5 mL (2.5 mg) every 4 hours; not to exceed 6 doses/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Triamanic&reg; Thin Strips&reg; Cold with Stuffy Nose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children 4-6 years: 1 strip (2.5 mg/strip) every 4 hours; not to exceed 6 doses/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children &gt;6 to 12 years: 2 strips (2.5 mg/strip) every 4 hours; not to exceed 6 doses/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Phenylephrine tannate salt: Ah-Chew D&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 6-12 years: 5-10 mg (2.5-5 mL) every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &gt;12 years and Adults: 10-20 mg (5-10 mL) every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotension/shock:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.M., SubQ: 0.1 mg/kg/dose or 3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 1-2 hours as needed; (maximum dose: 5 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V. bolus: 5-20 mcg/kg/dose every 10-15 minutes as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V. infusion: 0.1-0.5 mcg/kg/minute, titrate to desired effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.M., SubQ: 2-5 mg/dose every 1-2 hours as needed; reported effective dosage range: 1-10 mg; (initial dose should not exceed 5 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V. bolus: 0.2 mg/dose (range: 0.1-0.5 mg/dose) every 10-15 minutes as needed (initial dose should not exceed 0.5 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V. infusion: 100-180 mcg/minute,",
"     <b>",
"      or alternatively",
"     </b>",
"     , 0.5 mcg/kg/minute; titrate to desired response. Dosing ranges between 0.4-9.1 mcg/kg/minute have been reported (Gregory, 1991)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paroxysmal supraventricular tachycardia: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: 5-10 mcg/kg over 20-30 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: Initial: 0.25-0.5 mg over 20-30 seconds; subsequent doses may be increased in 0.1-0.2 mg increments; not to exceed 1 mg/dose (maximum dose of 2 mg is recommended by some clinicians)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9505013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 1% [10 mg/mL] (1 mL, 5 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PediaCare&reg; Children's Decongestant: 2.5 mg/5 mL (118 mL) [contains sodium 14 mg/5 mL, sodium benzoate; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sudafed PE&reg; Children's: 2.5 mg/5 mL (118 mL) [ethanol free, sugar free; contains sodium 14 mg/5 mL, sodium benzoate; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Medi-First&reg; Sinus Decongestant: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Medi-Phenyl: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sudafed PE&reg; Congestion: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sudafed PE&trade; Nasal Decongestant: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sudogest&trade; PE: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9504775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes liquid",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10514390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer without regard to food; place orally dissolving tablet (N��Sop&trade;) or Triaminic&reg; Thin Strips&reg; on tongue and allow to dissolve",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: For direct I.V. administration, dilute to 1 mg/mL by adding 1 mL to 9 mL of SWI, then administer dose over 20-30 seconds; continuous infusion concentrations are usually 20-60 mcg/mL by adding 5 mg to 250 mL I.V. solution (20 mcg/mL) or 15 mg to 250 mL (60 mcg/mL); rate of infusion (mL/hour) = dose (mcg/kg/minute) x weight (kg) x 60 minutes/hour divided by concentration (mcg/mL); administer into a large vein to prevent the possibility of extravasation; use infusion device to control rate of flow; administration into an umbilical arterial catheter is",
"     <b>",
"      not",
"     </b>",
"     recommended",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14473054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     20",
"     <b>",
"      mcg",
"     </b>",
"     /mL, 40",
"     <b>",
"      mcg",
"     </b>",
"     /mL, or 60",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F9504868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     R, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, R,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS, sodium bicarbonate 5%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amiodarone, anidulafungin, argatroban, bivalirudin, caffeine citrate, caspofungin, cisatracurium, doripenem, ethyl alcohol, etomidate, famotidine, fenoldopam, haloperidol, hetastarch in lactate electrolyte injection (Hextend&reg;), inamrinone, levofloxacin, micafungin, potassium chloride, remifentanil, telavancin, vasopressin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Furosemide, nesiritide, propofol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Caffeine citrate.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10514237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; protect from light; compatible when admixed with dextrose, dextrose-saline, Ringer's, LR, NS, and 1/6M sodium lactate injection; do not use if solution turns brown or contains a precipitate",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10514175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypotension and vascular failure in shock; supraventricular tachycardia; as a vasoconstrictor in regional analgesia; as a decongestant [OTC]",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9504764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Sudafed PE&reg; may be confused with Sudafed&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9504822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia (rare), decreased cardiac output, hypertension, pallor, precordial pain or discomfort, reflex bradycardia, severe peripheral and visceral vasoconstriction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, excitability, giddiness, headache, insomnia, nervousness, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Metabolic acidosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Gastric irritation, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: I.V.: Extravasation which may lead to necrosis and sloughing of surrounding tissue, blanching of skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, pilomotor response, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Decreased renal perfusion, reduced urine output",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory distress",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions (including rash, urticaria, leukopenia, agranulocytosis, thrombocytopenia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oral:",
"     </b>",
"     Central nervous system: Anxiety, dizziness, excitability, giddiness, headache, insomnia, nervousness, restlessness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10514179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phenylephrine or any component; pheochromocytoma, severe hypertension, ventricular tachycardia; acute pancreatitis, hepatitis; peripheral or mesenteric vascular thrombosis, myocardial disease, severe coronary disease, asthma; MAO inhibitor therapy or within 2 weeks of discontinuation of MAO inhibitor",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10514228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use as pressor therapy for treatment of hypotension and vascular failure is not a substitute for replacement of blood, plasma, and body fluids; use with caution in patients with hyperthyroidism, bradycardia, partial heart block, myocardial disease, or severe arteriosclerosis; infuse into large veins to prevent extravasation which may cause severe necrosis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10514183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety and efficacy for the use of cough and cold products in children &lt;2 years of age is limited. Serious adverse effects including death have been reported. The FDA notes that there are no approved OTC uses for these products in children &lt;2 years of age. Healthcare providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Do not use if solution turns brown or contains a precipitate. Injection may contain sulfites which may cause allergic reactions in susceptible individuals. Some formulations contain sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (\"gasping syndrome\") in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites; avoid use of benzyl alcohol containing products in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9504824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine.  Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9504777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9504778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted; therefore, the manufacturer classifies phenylephrine as pregnancy category C. Phenylephrine crosses the placenta at term. Maternal use of phenylephrine during the first trimester of pregnancy is not strongly associated with an increased risk of fetal malformations; maternal dose and duration of therapy were not reported in available publications. Phenylephrine is available over-the-counter (OTC) for the symptomatic relief of nasal congestion. Decongestants are not the preferred agents for the treatment of rhinitis during pregnancy. Oral phenylephrine should be avoided during the first trimester of pregnancy; short-term use (&lt;3 days) of intranasal phenylephrine may be beneficial to some patients although its safety during pregnancy has not been studied. Phenylephrine injection is used at delivery for the prevention and/or treatment of maternal hypotension associated with spinal anesthesia in women undergoing cesarean section. Phenylephrine may be associated with a more favorable fetal acid base status than ephedrine; however, overall fetal outcomes appear to be similar. Nausea or vomiting may be less with phenylephrine than ephedrine but is also dependent upon blood pressure control. Phenylephrine may be preferred in the absence of maternal bradycardia.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10514391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure, central venous pressure, arterial blood gases (hypotension/shock treatment)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10514238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potent, direct-acting alpha-adrenergic stimulator with weak beta-adrenergic activity; produces systemic arterial vasoconstriction",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10514278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Blood pressure increase/vasoconstriction:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.M.: Within 10-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: Following parenteral injection, effects occur immediately",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     SubQ: 10-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Nasal decongestant: Oral: 15-30 minutes (Kollar, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M.: 30 minutes to 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: 15-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     SubQ: 1 hour",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10514279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Oral: Rapid and complete (Kanfer, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     initial: 26-61 L; V",
"     <sub>",
"      dss",
"     </sub>",
"     184-543 L (mean 340 L) (Hengstmann, 1982)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via oxidative deamination (oral: 24%; I.V.: 50%); undergoes sulfation [oral (mostly within gut wall): 46%; I.V.: 8%] and some glucuronidation; forms inactive metabolites (Kanfer, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Oral: &le;38% (Hengstmann, 1982; Kanfer, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: Alpha phase: ~5 minutes: terminal phase: 2-3 hours (Hengstmann, 1982; Kanfer, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: Oral: 0.75-2 hours (Kanfer, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Urine (mostly as inactive metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brierley J, Carcillo JA, Choong K, et al, \"Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update From the American College of Critical Care Medicine,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2009, 37(2):666-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/23/13686/abstract-text/19325359/pubmed\" id=\"19325359\" target=\"_blank\">",
"        19325359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gregory JS, Bonfiglio MF, Dasta JF, et al, \"Experience With Phenylephrine as a Component of the Pharmacologic Support of Septic Shock,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1991, 19(11):1395-400.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/23/13686/abstract-text/1935160/pubmed\" id=\"1935160\" target=\"_blank\">",
"        1935160",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hengstmann JH and Goronzy J, \"Pharmacokinetics of 3H-Phenylephrine in Man,\"",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1982, 21(4):335-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/23/13686/abstract-text/7056280/pubmed\" id=\"7056280\" target=\"_blank\">",
"        7056280",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kanfer I, Dowse R, and Vuma V, \"Pharmacokinetics of Oral Decongestants,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1993, 13(6 Pt 2):116-128.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/23/13686/abstract-text/7507589/pubmed\" id=\"7507589\" target=\"_blank\">",
"        7507589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kollar C, Schneider H, Waksman J, et al, \"Meta-Analysis of the Efficacy of a Single Dose of Phenylephrine 10 mg Compared With Placebo in Adults With Acute Nasal Congestion Due to the Common Cold,\"",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2007, 29(6):1057-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/23/13686/abstract-text/17692721/pubmed\" id=\"17692721\" target=\"_blank\">",
"        17692721",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, \"Standardizing I.V. Infusion Concentrations: National Survey Results,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/23/13686/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16040 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.61.31.66-186E1AD1F7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_23_13686=[""].join("\n");
var outline_f13_23_13686=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504748\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504766\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514172\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808756\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514284\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505013\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504775\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514390\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473054\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504868\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514237\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514175\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504764\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504822\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514179\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514228\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514183\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299870\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504824\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504777\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504778\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514391\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514238\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514278\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514279\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16040\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16040|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/7/19572?source=related_link\">",
"      Phenylephrine (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/52/21316?source=related_link\">",
"      Phenylephrine (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/10/17572?source=related_link\">",
"      Phenylephrine (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/7/23668?source=related_link\">",
"      Phenylephrine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/50/37668?source=related_link\">",
"      Phenylephrine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/13/40147?source=related_link\">",
"      Phenylephrine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/47/6903?source=related_link\">",
"      Phenylephrine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/59/33717?source=related_link\">",
"      Phenylephrine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/53/30547?source=related_link\">",
"      Phenylephrine (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/36/20036?source=related_link\">",
"      Phenylephrine (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/16/5379?source=related_link\">",
"      Phenylephrine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_23_13687="Sulfonylurea agent poisoning";
var content_f13_23_13687=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sulfonylurea agent poisoning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/23/13687/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/23/13687/contributors\">",
"     Jason Chu, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/23/13687/contributors\">",
"     Andrew Stolbach, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/23/13687/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/23/13687/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/23/13687/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/23/13687/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/23/13687/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/23/13687/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sulfonylurea agents are commonly used in the treatment of diabetes mellitus. When used appropriately, they promote euglycemia, although hypoglycemia can occur if clearance is impaired or the patient does not eat. Sulfonylureas often cause hypoglycemia with overdose or when ingested by nondiabetic patients.",
"   </p>",
"   <p>",
"    The hypoglycemic effects of the sulfonamide antibacterial agents were first discovered in the 1940s. The derivative sulfonylurea medications were first used to treat diabetes mellitus type 2 in 1954, and they remain in widespread use today [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/1\">",
"     1",
"    </a>",
"    ]. Sulfonylureas may be used alone when diet control has failed or in combination with other oral drugs.",
"   </p>",
"   <p>",
"    Patients over 65 years, those taking multiple medications, and those who are frequently hospitalized are at increased risk for hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Sulfonylurea related hypoglycemia may be seen in the setting of unintentional ingestion. Ingestion of a single sulfonylurea pill (ie, 2 mg) by a toddler can cause hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of sulfonylurea toxicity will be reviewed here. The therapeutic use of sulfonylureas and other antihyperglycemic agents, the toxicology of other antihyperglycemic agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , and the general clinical management of drug intoxication are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35559?source=see_link\">",
"     \"Sulfonylureas and meglitinides in the treatment of diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21799?source=see_link\">",
"     \"Metformin poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY AND TOXICOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sulfonylurea medications inhibit ATP-sensitive potassium channels in pancreatic beta cell membranes. These potassium channels normally allow for potassium efflux from the cell. Inhibition leads to elevated intracellular potassium levels, which results in depolarization. Depolarization causes calcium influx, which activates the secretory system that releases insulin. Sulfonylureas also promote exocytosis of insulin through distinct mechanisms involving direct binding of pancreatic beta cell receptors. In summary, sulfonylurea medications promote hypoglycemia by increasing the release of endogenous insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The toxicity of sulfonylurea agents is a direct extension of their normal pharmacology. When used inappropriately (in overdose or in patients without diabetes), hypoglycemia can result.",
"   </p>",
"   <p>",
"    Several drug and patient related factors increase the risk of hypoglycemia. Sulfonylurea agents with longer durations of action (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/0/6151?source=see_link\">",
"     chlorpropamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    ) are more likely to cause such reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/1,8\">",
"     1,8",
"    </a>",
"    ]. Impaired drug clearance contributes to toxicity in some cases, and renal insufficiency is associated with a fourfold risk of hypoglycemia in patients taking sulfonylureas.",
"   </p>",
"   <p>",
"    Drug interactions may also cause hypoglycemia through a number of mechanisms, including decreased hepatic metabolism, increased hypoglycemic activity, and displacement of drug from plasma proteins (",
"    <a class=\"graphic graphic_table graphicRef64887 \" href=\"UTD.htm?16/8/16523\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. Several case reports document persistent hypoglycemia resulting from the interaction of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/46/4836?source=see_link\">",
"     gatifloxacin",
"    </a>",
"    with sulfonylurea agents [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/10\">",
"     10",
"    </a>",
"    ]. The mechanism of this interaction is unknown, but it appears to be unique to gatifloxacin and is not a quinolone class effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     KINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sulfonylureas possess a broad range of pharmacokinetic properties (",
"    <a class=\"graphic graphic_table graphicRef72580 \" href=\"UTD.htm?29/3/29756\">",
"     table 2",
"    </a>",
"    ). In overdose, their onset of action remains unchanged, but their duration of action increases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/11\">",
"     11",
"    </a>",
"    ]. Peak plasma concentrations are generally achieved within eight hours of an acute ingestion.",
"   </p>",
"   <p>",
"    Sulfonylureas are metabolized by the liver. Some agents have active metabolites that are renally excreted (",
"    <a class=\"graphic graphic_table graphicRef51723 \" href=\"UTD.htm?22/45/23259\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The sulfonylureas are extensively protein bound [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/1\">",
"     1",
"    </a>",
"    ]. The duration of activity, hepatic metabolism, and renal excretion all have implications in the management of patients presenting with sulfonylurea related hypoglycemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HISTORY AND PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;If possible, clinicians should ask patients about the amount, timing, and reason for any ingestion, what drug was taken, and coingestants including other diabetic medications. Coingestants may mask autonomic symptoms of sulfonylurea overdose. The clinician should attempt to identify any recent illness that may have triggered sulfonylurea-induced hypoglycemia. Age greater than 65 years, taking multiple medications, frequent hospitalization, renal insufficiency, and poor management of diabetes have been associated with sulfonylurea-induced hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/1,2,12\">",
"     1,2,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The remainder of the history and physical examination should focus on identifying the manifestations of hypoglycemia, often divided into neuroglycopenic and autonomic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link\">",
"     \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neuroglycopenia describes insufficient brain glucose. Common symptoms include confusion, difficulty speaking, dizziness, hemiparesis, seizures, or coma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/13\">",
"     13",
"    </a>",
"    ]. In short, neuroglycopenia can mimic virtually any neurologic condition.",
"   </p>",
"   <p>",
"    Autonomic symptoms are caused by counterregulatory hormones, especially epinephrine, and include anxiety, nausea, sweating, and palpitations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to one retrospective chart review of 59 patients, the most common neuroglycopenic symptoms are confusion (83 percent) and personality change (64 percent), while the most common autonomic complaints are diaphoresis (69 percent) and tremulousness (24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In infants and young children, the signs of hypoglycemia are frequently nonspecific. They may include irritability, lethargy, abnormal behavior, and with severe hypoglycemia can progress to seizure and coma. Autonomic symptoms are less prominent. With repeated episodes of hypoglycemia, severe manifestations can appear suddenly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=see_link\">",
"     \"Approach to hypoglycemia in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no consistent chronologic order to the evolution of hypoglycemic symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When hypoglycemia is absent following an unintentional exposure, additional testing is generally unnecessary. Patients with known or suspected sulfonylurea poisoning should have a serum creatinine measured, as a decrease in renal clearance may contribute to toxicity. Serial measurements of serum glucose and baseline measurements of serum electrolytes are appropriate. Further testing is determined clinically. As an example, urine myoglobin and serum creatine kinase are appropriate tests in a patient found on the ground and unresponsive, and thought to be at risk for rhabdomyolysis.",
"   </p>",
"   <p>",
"    Routine laboratory evaluation of any poisoned patient, particularly those with a suspected intentional overdose, includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status. This is particularly important in patients who have taken sulfonylurea agents.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      and salicylate levels, to rule out these common coingestions.",
"     </li>",
"     <li>",
"      Electrocardiogram, to rule out conduction system poisoning by coingestants that effect the QRS or QTc intervals.",
"     </li>",
"     <li>",
"      Pregnancy test, when appropriate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;If sulfonylurea overdose is diagnosed and treated quickly, patients generally recover without sequelae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;When hypoglycemia is recognized, intravenous dextrose (D-glucose) is administered (0.5 to 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    IV) to increase blood glucose levels acutely. Symptomatic hypoglycemia from intentional sulfonylurea overdose is treated with both dextrose and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    ; the role of octreotide in hypoglycemia associated with therapeutic use of sulfonylureas is unclear. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Symptomatic intentional overdose'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H10\">",
"     'Unintentional single-episode hypoglycemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In adults, the initial treatment is generally 25 grams (50 mLs) of 50 percent dextrose (D50W) solution. In infants and children, a weight-based bolus of dextrose (0.5 to 1",
"    <span class=\"nowrap\">",
"     g/kg)",
"    </span>",
"    is given IV. Children are treated with a 25 percent (D25W) or 10 percent (D10W) dextrose solution, and neonates with a 10 percent dextrose solution. Doses of dextrose may be repeated.",
"   </p>",
"   <p>",
"    Basic pediatric dosing is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      D10W: give 5 to 10",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"     </li>",
"     <li>",
"      D25W: give 2 to 4",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"     </li>",
"     <li>",
"      D50W: give 1 to 2",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If thiamine deficiency (from alcoholism or other forms of malnutrition) is suspected, parenteral thiamine (100 mg IV) is given in conjunction with glucose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10217?source=see_link\">",
"     \"Wernicke's encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     Glucagon",
"    </a>",
"    (5 mg) given intramuscularly (IM) raises serum glucose levels slightly and may be used as a temporizing measure while IV access is obtained, but it is not a substitute for dextrose [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/16\">",
"     16",
"    </a>",
"    ]. The efficacy of glucagon is dependent upon hepatic glycogen stores, which may be depleted in the setting of prolonged hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/11\">",
"     11",
"    </a>",
"    ]. The short duration of action of glucagon further limits its effectiveness.",
"   </p>",
"   <p>",
"    Once clinical euglycemia is established based on clinical findings, and generally accompanied by a serum glucose &ge;60",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.3",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    the patient should be fed a calorie-rich meal. Fifty mLs of 50 percent dextrose in sterile water (D50W) contains only 25 g of dextrose or 100 calories, whereas food provides a calorie-rich and longer lasting source of glucose.",
"   </p>",
"   <p>",
"    Further treatment and disposition vary depending on the class of agent causing the toxicity and the severity of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Intoxication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician is most likely to encounter one of three possible intoxication scenarios: a patient with a sulfonylurea overdose and symptomatic hypoglycemia; a patient who develops a hypoglycemic episode with therapeutic use of a sulfonylurea agent; and the asymptomatic (usually pediatric) patient with an acute exposure and a normal serum glucose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Symptomatic intentional overdose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with a sulfonylurea overdose and symptomatic hypoglycemia should be treated with both intravenous dextrose and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    . Intravenous dextrose is administered, as described above, to raise the blood glucose level acutely, thereby increasing glucose delivery to the brain. Octreotide is a somatostatin analog that inhibits insulin release from pancreatic beta-islet cells. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Hypoglycemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Intravenous dextrose, while crucial for resuscitation, should not be used as monotherapy for a sulfonylurea overdose. When given alone, IV dextrose may cause a transient hyperglycemia that triggers increased insulin release, leading to recurrent episodes of hypoglycemia. This increase in insulin release can be minimized by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    . In adults, the dose of octreotide is 50 to 150 micrograms (mcg) administered by intramuscular, or subcutaneous, injection every six hours; in children the dose is 1 to 1.5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    (up to 150 mcg) every six hours. Octreotide may also be given as an IV bolus over several minutes or by continuous IV infusion.",
"   </p>",
"   <p>",
"    Serum glucose should be periodically monitored to identify recurrence of hypoglycemia. The optimal interval is not known. Once the initial hypoglycemia is corrected, we suggest measuring blood glucose twice more at 30 minute intervals. If the patient maintains euglycemia, serum glucose can be checked every four to six hours thereafter.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    is administered for 24 hours. After octreotide is discontinued, the patient is monitored for hypoglycemia for another 24 hours to ensure there is no remaining drug or active metabolite. If hypoglycemia recurs during this period, we suggest restarting octreotide therapy for another 24 hours. In addition, we obtain two serum glucose measurements 30 minutes apart during the first hour, and every four to six hours thereafter, provided euglycemia is maintained.",
"   </p>",
"   <p>",
"    A small number of controlled trials and multiple case reports describe successful treatment of sulfonylurea-related hypoglycemia with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    in pediatric, adult, diabetic, and nondiabetic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/1,17-21\">",
"     1,17-21",
"    </a>",
"    ]. A retrospective review of nine patients treated for sulfonylurea-related hypoglycemia showed that 2.9 ampules of D50W were needed for each patient before octreotide treatment but only 0.2 ampules thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/17\">",
"     17",
"    </a>",
"    ]. The risk for hypoglycemia before octreotide treatment was 27 times the risk of hypoglycemia after treatment. A small, limited randomized trial found that patients treated with a single dose of octreotide in addition to standard care maintained higher serum glucose levels over eight hours and sustained fewer episodes of hypoglycemia than patients treated with standard care alone [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several mechanisms of action have been proposed for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , but the most important is thought to be a G-protein-mediated decrease in calcium influx through voltage-gated channels in pancreatic beta islet cells. Decreased calcium influx diminishes calcium-mediated insulin release [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/23\">",
"     23",
"    </a>",
"    ]. The drug is rapidly and completely absorbed when given subcutaneously, reaching 100 percent bioavailability within 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    has replaced",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/38/13924?source=see_link\">",
"     diazoxide",
"    </a>",
"    as a treatment for sulfonylurea-induced hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/11,25\">",
"     11,25",
"    </a>",
"    ]. Diazoxide hyperpolarizes the islet cell membrane, inhibiting calcium influx and thus the calcium-dependent release of insulin. A study comparing dextrose, diazoxide, and octreotide in normal volunteers showed that octreotide produces a significantly greater decrease in insulin secretion and glucose requirements [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/25\">",
"     25",
"    </a>",
"    ]. Diazoxide can also cause hypotension.",
"   </p>",
"   <p>",
"    In the presence of an acute overdose (ie, within two hours),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC) may be given to prevent absorption of the sulfonylurea. Charcoal should be withheld in patients who are sedated and may not be able to protect their airway, unless endotracheal intubation is performed first. Endotracheal intubation should not be performed solely for the purpose of giving charcoal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum electrolytes should also be obtained.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/0/6151?source=see_link\">",
"     Chlorpropamide",
"    </a>",
"    has been associated with dose-independent symptomatic hyponatremia related to inappropriate secretion of antidiuretic hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\", section on 'Drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are limited data on hemodialysis for sulfonylurea ingestions. The drugs exhibit high protein binding, which theoretically makes hemodialysis ineffective. There are a few case reports of hemoperfusion being used successfully in a sulfonylurea overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Unintentional single-episode hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of the patient with a single episode of hypoglycemia during therapeutic sulfonylurea use (not overdose) is less straightforward. Intravenous dextrose is appropriate to correct symptomatic hypoglycemia, but the role for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    is less clear. We recommend feeding such patients a calorie-rich meal, holding their sulfonylurea medication, and observing them in the hospital for 24 hours. We do not suggest octreotide therapy for a single episode of hypoglycemia under these circumstances.",
"   </p>",
"   <p>",
"    If the patient remains euglycemic during the 24 hour observation period, we believe that the patient may be safely discharged. If the patient develops a second episode of hypoglycemia, we recommend that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    be administered in the same manner and monitoring schedule as described above for patients with an overdose. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Hypoglycemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The management of patients who present to their primary care physicians (PCP) with mild symptoms of hypoglycemia during therapeutic sulfonylurea use may differ from that of patients who present to the emergency department. PCPs who know the patient well may elect to discharge the patient home after a thorough evaluation and a period of observation, provided the following criteria are met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms are mild and resolve rapidly and completely following simple treatment (eg, juice and a meal), and do not recur over a few hours of observation.",
"     </li>",
"     <li>",
"      There is a clear history of inadequate food intake preceding the development of symptoms.",
"     </li>",
"     <li>",
"      Serum glucose is maintained above 80",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.4",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      over a few hours of observation.",
"     </li>",
"     <li>",
"      History, physical examination, and possibly laboratory studies (eg, BUN and creatinine) do not raise concerns about comorbid disease or impaired drug clearance.",
"     </li>",
"     <li>",
"      Responsible caretakers will remain with the patient for the next 24 hours to ensure that finger stick blood sugars are monitored closely (eg, every four hours), remain over 80",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.4",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      and that symptoms do not recur.",
"     </li>",
"     <li>",
"      Appropriate follow-up is arranged.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Observation in the hospital is indicated if he or she does not meet all these criteria, or if the clinician has concerns about the patient's condition or whether appropriate monitoring can be performed at home.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Pediatric considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of an asymptomatic, euglycemic child presenting with a history of a sulfonylurea exposure is difficult. Ingestions of a single sulfonylurea pill as small as 2 mg can cause hypoglycemia in young children.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     Activated charcoal",
"    </a>",
"    should be given if it is within two hours of the ingestion and the patient will tolerate it. Activated charcoal is unlikely to be effective in symptomatic children since hypoglycemia from sulfonylurea often occurs hours after the ingestion.",
"   </p>",
"   <p>",
"    We recommend in-hospital observation for 24 hours for any child with a sulfonylurea exposure because delayed hypoglycemia has occurred following ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13687/abstract/3,4,29-31\">",
"     3,4,29-31",
"    </a>",
"    ]. If the patient becomes hypoglycemic, standard treatment is provided. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Hypoglycemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The dose of sulfonylurea necessary to cause hypoglycemia in small children is difficult to determine based on available evidence, and will depend on a range of factors, such as when the child last ate, whether the child is ill or malnourished, and the size of the child. It is best to err on the side of caution and observe the child in the hospital if any doubt exists about the nature of the ingestion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sulfonylurea agents are commonly used in the treatment of diabetes mellitus, but can cause hypoglycemia. Risk factors for hypoglycemia from therapeutic use include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Age over 65 years",
"     </li>",
"     <li>",
"      Multiple medications",
"     </li>",
"     <li>",
"      Frequent hospitalization",
"     </li>",
"     <li>",
"      Use of agents with longer durations of action (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/0/6151?source=see_link\">",
"       chlorpropamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"       glyburide",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Impaired drug clearance (eg, renal or hepatic dysfunction); renal insufficiency can increase the risk of hypoglycemia fourfold",
"      <br/>",
"      <br/>",
"      The pharmacology and kinetics of these agents are described in detail above. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacology and toxicology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Kinetics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inquire about the amount, timing, and reason for any ingestion, what drug was taken, and coingestants, including other diabetic medications. Hypoglycemia generally manifests with neurologic and autonomic symptoms. Among the most common are confusion, personality change, diaphoresis, and tremulousness, but symptoms can be masked by coingestants. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'History and physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For any patient with an intentional overdose or at risk for poisoning from other agents, obtain the following studies: fingerstick glucose,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      and salicylate levels, serum creatinine, electrocardiogram, and a pregnancy test, when appropriate. Serial measurements of serum glucose and baseline measurements of serum electrolytes are appropriate. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient with a sulfonylurea overdose and symptomatic hypoglycemia is immediately treated with intravenous (IV) dextrose. In addition, we suggest immediate treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In adults the dose of dextrose is 0.5 to 1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      IV. The initial bolus is generally given as 25 grams (50 mL) of 50 percent dextrose (D50W) solution. In infants and children a weight-based bolus of dextrose (0.25",
"      <span class=\"nowrap\">",
"       g/kg)",
"      </span>",
"      is given IV. A 10 percent or 25 percent dextrose solution may used. In adults, the dose of octreotide is 50 to 150 micrograms administered by intramuscular, or subcutaneous, injection every six hours; in children the dose is 1 to 1.5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      (up to 50 mcg) every six hours. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Symptomatic intentional overdose'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Hypoglycemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the patient with a single episode of hypoglycemia during therapeutic sulfonylurea use (not overdose), treatment consists of IV dextrose followed by a calorie-rich meal, discontinuation of sulfonylurea medications, and 24 hours of in-hospital observation with close monitoring of the serum glucose. Primary care physicians may elect to discharge home patients they know well who present to the clinic with mild symptoms of hypoglycemia during therapeutic sulfonylurea, provided several important criteria are met. These criteria are described in the text. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Unintentional single-episode hypoglycemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Hypoglycemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any child with a possible sulfonylurea exposure should be observed in the hospital for 24 hours. Delayed hypoglycemia has occurred following ingestion of a number of medications, and a single sulfonylurea pill as small as 2 mg can cause hypoglycemia in young children. If the patient becomes hypoglycemic, standard treatment is provided. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pediatric considerations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Hypoglycemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/1\">",
"      Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994; 11:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/2\">",
"      Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997; 157:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/3\">",
"      Quadrani DA, Spiller HA, Widder P. Five year retrospective evaluation of sulfonylurea ingestion in children. J Toxicol Clin Toxicol 1996; 34:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/4\">",
"      Robertson WO. Delayed hypoglycemia after ingestion of a single glipizide tablet. Ann Emerg Med 1999; 33:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/5\">",
"      Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989; 321:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/6\">",
"      Spiller HA, Sawyer TS. Toxicology of oral antidiabetic medications. Am J Health Syst Pharm 2006; 63:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/7\">",
"      Eliasson L, Renstr&ouml;m E, Amm&auml;l&auml; C, et al. PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic beta cells. Science 1996; 271:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/8\">",
"      Stahl M, Berger W. Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabet Med 1999; 16:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/9\">",
"      Harrigan RA, Nathan MS, Beattie P. Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment. Ann Emerg Med 2001; 38:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/10\">",
"      Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH. Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents. Am J Med 2002; 113:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/11\">",
"      Spiller HA. Management of sulfonylurea ingestions. Pediatr Emerg Care 1999; 15:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/12\">",
"      Holstein A, Hammer C, Hahn M, et al. Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. Expert Opin Drug Saf 2010; 9:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/13\">",
"      Dizon AM, Kowalyk S, Hoogwerf BJ. Neuroglycopenic and other symptoms in patients with insulinomas. Am J Med 1999; 106:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/14\">",
"      Hepburn DA, Deary IJ, Frier BM, et al. Symptoms of acute insulin-induced hypoglycemia in humans with and without IDDM. Factor-analysis approach. Diabetes Care 1991; 14:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/15\">",
"      Towler DA, Havlin CE, Craft S, Cryer P. Mechanism of awareness of hypoglycemia. Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes 1993; 42:1791.",
"     </a>",
"    </li>",
"    <li>",
"     Bosse GM. Antidiabetic and hypoglycemic agents. In: Goldfrank's Toxicologic Emergencies, 7th, Goldfrank LR, Flomenbaum NE, Lewin NA, et al.  (Eds), McGraw-Hill, New York 2002. p.593.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/17\">",
"      McLaughlin SA, Crandall CS, McKinney PE. Octreotide: an antidote for sulfonylurea-induced hypoglycemia. Ann Emerg Med 2000; 36:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/18\">",
"      Braatvedt GD. Octreotide for the treatment of sulphonylurea induced hypoglycaemia in type 2 diabetes. N Z Med J 1997; 110:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/19\">",
"      Carr R, Zed PJ. Octreotide for sulfonylurea-induced hypoglycemia following overdose. Ann Pharmacother 2002; 36:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/20\">",
"      Rath S, Bar-Zeev N, Anderson K, et al. Octreotide in children with hypoglycaemia due to sulfonylurea ingestion. J Paediatr Child Health 2008; 44:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/21\">",
"      Glatstein M, Scolnik D, Bentur Y. Octreotide for the treatment of sulfonylurea poisoning. Clin Toxicol (Phila) 2012; 50:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/22\">",
"      Fasano CJ, O'Malley G, Dominici P, et al. Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia. Ann Emerg Med 2008; 51:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/23\">",
"      Hsu WH, Xiang HD, Rajan AS, et al. Somatostatin inhibits insulin secretion by a G-protein-mediated decrease in Ca2+ entry through voltage-dependent Ca2+ channels in the beta cell. J Biol Chem 1991; 266:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/24\">",
"      Kutz K, N&uuml;esch E, Rosenthaler J. Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol Suppl 1986; 119:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/25\">",
"      Boyle PJ, Justice K, Krentz AJ, et al. Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses. J Clin Endocrinol Metab 1993; 76:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/26\">",
"      Piters K. Chlorpropamide-induced hyponatremia. J Clin Endocrinol Metab 1976; 43:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/27\">",
"      Ludwig SM, McKenzie J, Faiman C. Chlorpropamide overdose in renal failure: management with charcoal hemoperfusion. Am J Kidney Dis 1987; 10:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/28\">",
"      Moore DF, Wood DF, Volans GN. Features, prevention and management of acute overdose due to antidiabetic drugs. Drug Saf 1993; 9:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/29\">",
"      Szlatenyi CS, Capes KF, Wang RY. Delayed hypoglycemia in a child after ingestion of a single glipizide tablet. Ann Emerg Med 1998; 31:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/30\">",
"      Palatnick W, Meatherall RC, Tenenbein M. Clinical spectrum of sulfonylurea overdose and experience with diazoxide therapy. Arch Intern Med 1991; 151:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13687/abstract/31\">",
"      Lung DD, Olson KR. Hypoglycemia in pediatric sulfonylurea poisoning: an 8-year poison center retrospective study. Pediatrics 2011; 127:e1558.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 308 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-C0B5FDA9AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_23_13687=[""].join("\n");
var outline_f13_23_13687=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY AND TOXICOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      KINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HISTORY AND PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Intoxication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Symptomatic intentional overdose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Unintentional single-episode hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Pediatric considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/308\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/308|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/8/16523\" title=\"table 1\">",
"      Drugs that potentiate the action of sulfonylureas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/3/29756\" title=\"table 2\">",
"      Sulfonylurea kinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/45/23259\" title=\"table 3\">",
"      Sulfonylurea with renally-eliminated active metabolites",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=related_link\">",
"      Approach to hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21799?source=related_link\">",
"      Metformin poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=related_link\">",
"      Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35559?source=related_link\">",
"      Sulfonylureas and meglitinides in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10217?source=related_link\">",
"      Wernicke's encephalopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_23_13688="Parathyroid carcinoma";
var content_f13_23_13688=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Parathyroid carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/23/13688/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/23/13688/contributors\">",
"     Ghada El-Hajj Fuleihan, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/23/13688/contributors\">",
"     Andrew Arnold, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/23/13688/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/23/13688/contributors\">",
"     Marc K Drezner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/23/13688/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/23/13688/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/23/13688/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hyperparathyroidism is usually caused by a parathyroid adenoma, occasionally by primary parathyroid hyperplasia, and rarely by a parathyroid carcinoma or parathyroid cyst, and very rarely by ectopic secretion of PTH from a nonparathyroid tumor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30361?source=see_link\">",
"     \"Pathogenesis and etiology of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will provide an overview of parathyroid carcinoma. Other aspects of primary hyperparathyroidism are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link\">",
"     \"Clinical manifestations of primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link\">",
"     \"Management of primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18377?source=see_link\">",
"     \"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40387?source=see_link\">",
"     \"Parathyroid cysts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=see_link\">",
"     \"Parathyroid exploration for primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parathyroid carcinoma is a rare cause of hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/1\">",
"     1",
"    </a>",
"    ]. In one review of 4239 patients with hyperparathyroidism, 2.1 percent had functioning parathyroid carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/2\">",
"     2",
"    </a>",
"    ]. A systematic literature review of 22,225 cases of primary hyperparathyroidism reported between 1995 and 2003 revealed that parathyroid carcinoma accounted for 0.74 percent of the cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    From 1988 to 2003, 224 patients with parathyroid carcinoma were identified by the Surveillance, Epidemiology, and End Results (SEER) cancer registry data [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/4\">",
"     4",
"    </a>",
"    ]. During this time period, the incidence of parathyroid carcinoma increased from 3.58 to 5.73 per 10 million population. The increase was accompanied by a significant decrease in the proportion of patients with large (&ge;4 cm) tumors and increase in proportion with negative lymph nodes, suggesting that earlier diagnosis may account for the increased incidence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MOLECULAR PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutation of the HRPT2 (also called CDC73) tumor suppressor gene has been recognized to play a central role in the molecular pathogenesis of parathyroid carcinoma. HRPT2 is located on chromosome 1 and encodes parafibromin, a protein whose function remains under investigation but appears to involve regulation of gene expression and inhibition of cell proliferation.",
"   </p>",
"   <p>",
"    Inactivating germline mutations in the HRPT2 gene are responsible for an autosomal dominant type of familial hyperparathyroidism, the hyperparathyroidism-jaw tumor syndrome (HPT-JT) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients with HPT-JT are predisposed to ossifying fibromas of the jaw, cystic and neoplastic renal lesions, uterine tumors, and parathyroid neoplasia with an increased risk of parathyroid cancer. Parathyroid carcinoma was reported to occur in approximately 15 percent of patients with HPT-JT [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/6\">",
"     6",
"    </a>",
"    ]. Importantly, in HPT-JT all parathyroid glands are at risk for tumor development, but the tumors can occur asynchronously over many years.",
"   </p>",
"   <p>",
"    Sporadic (nonfamilial) parathyroid carcinomas frequently bear HRPT2 mutations. One of two original studies reported HRPT2 mutations in 10 of 15 sporadic parathyroid cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/7\">",
"     7",
"    </a>",
"    ], and the other identified such mutations in four of four carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/8\">",
"     8",
"    </a>",
"    ]. Most mutations were somatic [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/7\">",
"     7",
"    </a>",
"    ], implying a selective advantage that attests to their pathogenetic importance. Furthermore, because mutations outside the coding region are expected to occur but would have escaped detection, it is plausible that HRPT2 inactivation drives virtually all parathyroid cancers.",
"   </p>",
"   <p>",
"    Unsuspected germ-line mutations were also discovered in a substantial minority of patients who presented clinically with sporadic disease, suggesting that some of these individuals may have HPT-JT, or a phenotypic variant [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/7\">",
"     7",
"    </a>",
"    ]. This recognition that family members of some patients with apparently sporadic parathyroid cancer are also at risk for parathyroid malignancy has created a new indication for genetic testing. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Genetic testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other studies have confirmed the presence of HRPT2 mutations in both sporadic parathyroid carcinoma and in HPT-JT, as well as their rare presence in isolated familial hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In sporadic parathyroid cancer, combining results from three studies results in an impressive prevalence of 77 percent (20 of 26) for coding region mutations in HRPT2 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/7,8,10\">",
"     7,8,10",
"    </a>",
"    ]. Conversely, in the largest series of sporadic benign parathyroid adenomas reported to date, no intragenic mutations of the HRPT2 gene could be detected [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/11\">",
"     11",
"    </a>",
"    ]. Combining the latter study with one or more of the previous ones, depending upon criteria used to select the tumors, would lead to a prevalence as low as 0 percent (0 of 85) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/8,11\">",
"     8,11",
"    </a>",
"    ], or as high as 1.8 percent (3 of 167) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/5,8,10,11\">",
"     5,8,10,11",
"    </a>",
"    ] for HRPT2 mutations in parathyroid adenomas. The above cumulative analyses provide evidence that HRPT2 intragenic mutations are very highly specific to rigorously defined parathyroid carcinomas, as opposed to typical adenomas, and can be considered as a potentially useful diagnostic tool in atypical parathyroid neoplasms that lack the classical invasive or metastatic features of carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Immunohistochemical detection of the parafibromin protein may also provide diagnostically helpful information [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/13\">",
"     13",
"    </a>",
"    ], but its clinical utility also requires further study.",
"   </p>",
"   <p>",
"    Other genes, through somatic mutation, also appear to participate in the pathogenesis of parathyroid carcinoma but their identities remain to be established. As an example, evidence has implicated abnormal expression of the retinoblastoma and p53 proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], and a tumor suppressor gene on chromosome 13 in the vicinity of retinoblastoma gene may play a role in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. In another report, somatic mutations in the MEN 1 gene were found in 3 of 23 sporadic parathyroid carcinoma cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/17\">",
"     17",
"    </a>",
"    ], although diagnostic criteria for carcinoma differed from other studies in not requiring local invasion or metastases. No such mutations had previously been reported in parathyroid carcinoma, and this disease has not been considered to be part of the MEN 1-associated phenotype. MEN 1 is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17174?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Definition and genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major clinical manifestations of parathyroid carcinoma can be summarized from four studies involving a total of 314 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/2,18-20\">",
"     2,18-20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mean age &mdash; 44 to 54 years",
"     </li>",
"     <li>",
"      Mean serum calcium concentration &mdash; 14.6 to 15.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.7 to 4.0",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Serum calcium concentration above 14",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      &mdash; 65 to 75 percent",
"     </li>",
"     <li>",
"      Neck mass &mdash; 34 to 52 percent",
"     </li>",
"     <li>",
"      Bone disease &mdash; 34 to 73 percent",
"     </li>",
"     <li>",
"      Renal disease &mdash; 32 to 70 percent",
"     </li>",
"     <li>",
"      Pancreatitis &mdash; 0 to 15 percent",
"     </li>",
"     <li>",
"      No symptoms &mdash; 2 to 7 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whereas benign hyperparathyroidism is more common in women (3:1), the incidence of parathyroid cancer is equal between the two genders. Compared with patients with parathyroid adenomas, patients with parathyroid carcinomas are more likely to have symptoms, a neck mass, bone and kidney disease, marked hypercalcemia, and very high serum parathyroid hormone (PTH) concentrations (5 to 10-fold higher than the upper limit of normal) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/2,18-20\">",
"     2,18-20",
"    </a>",
"    ]. Up to one-third of subjects have lymph node metastases at initial presentation, and one-third have distant metastases, usually to liver and bone [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, parathyroid carcinoma should be suspected in a patient with primary hyperparathyroidism who has recurrent laryngeal nerve palsy. Predilection for a single inferior gland has been noted in case series [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Less than 10 percent of parathyroid carcinomas are hormonally non-functional, and such tumors usually present at a more advanced stage [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In view of the higher serum calcium values, it is not surprising that parathyroid carcinoma is present in a disproportionate fraction of patients with parathyroid crisis. In one review, as an example, parathyroid crisis was the presenting problem in 12 percent of patients with parathyroid carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the overlap in the clinical and biochemical presentation between benign disease and parathyroid carcinoma, a specific diagnosis may be difficult to establish and is often not available at the time of first surgery. It has been suggested that a preoperative diagnosis or suspicion for parathyroid carcinoma may lead to a more aggressive surgical excision and therefore a higher cure rate at the time of first surgery.",
"   </p>",
"   <p>",
"    A retrospective study of 311 cases of primary hyperparathyroidism, of which nine were parathyroid carcinomas, demonstrated that PTH levels less than four times the upper limit of normal and a tumor weight &lt;1.9 g, made the likelihood of parathyroid carcinoma essentially zero [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link\">",
"     \"Clinical manifestations of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Atypical presentations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most patients with parathyroid carcinoma have hypercalcemia, some patients remain normocalcemic; these patients often present with a neck mass. Nonfunctioning parathyroid carcinomas are rare, with fewer than 20 cases reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/25\">",
"     25",
"    </a>",
"    ]. In a review of 17 such cases, patients were reported to be diagnosed at a more advanced stage of disease, and their tumors may be more aggressive [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/26\">",
"     26",
"    </a>",
"    ]. Frequent locations for metastases include the lungs, cervical lymph nodes, liver, and bone [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/27\">",
"     27",
"    </a>",
"    ]. In contrast to patients with functional parathyroid cancers, patients with non-functional tumors die from mass effect and tumor burden, rather than from hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiglandular parathyroid carcinoma is also extremely rare [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;No single histopathologic feature is pathognomonic for parathyroid carcinoma. The histopathologic examination of parathyroid carcinoma may show uniform sheets of cells arranged in a lobular pattern separated by dense fibrous trabeculae, mitotic figures in the tumor cells, and capsular and blood vessel invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. However, these features have been noted occasionally in parathyroid adenomas. DNA content of tumor cell nuclei is also not specific for parathyroid carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/30\">",
"     30",
"    </a>",
"    ]. Gross invasion beyond the capsule and including extracapsular vascular invasion appear to correlate best with subsequent tumor recurrence. Thus, because of the nonspecificity of these histologic features, the two criteria upon which a definitive diagnosis of parathyroid carcinomas can be made are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Local invasion of contiguous structures or",
"     </li>",
"     <li>",
"      Lymph node or distant metastases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some cases it may not be possible to differentiate parathyroid adenoma or carcinoma at the time of diagnosis or initial surgery. Local recurrence or the occurrence of distal metastases at subsequent follow-up ultimately determines the correct pathological diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is the mainstay of therapy. The approach to initial surgery has evolved from an extremely aggressive procedure with ipsilateral thyroidectomy, isthmusectomy, excision of nearby strap muscles, and removal of the recurrent laryngeal nerve, if involved [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/20\">",
"     20",
"    </a>",
"    ], to a less aggressive one, namely parathyroidectomy or en-bloc resection of the parathyroid mass and any adjacent tissues that have been invaded by tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/22\">",
"     22",
"    </a>",
"    ]. In the SEER registry, 78.6 percent of patients had a simple parathyroidectomy, and 12.5 percent underwent en-bloc resection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    En-bloc resection could include the ipsilateral thyroid lobe, paratracheal alveolar and lymphatic tissue, the thymus or some of the neck muscles; and in some instances, the recurrent laryngeal nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/2,18-20\">",
"     2,18-20",
"    </a>",
"    ]. Some [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/20\">",
"     20",
"    </a>",
"    ], centers recommend ipsilateral lymph node dissection. It is important to avoid capsular violation or tumor spillage [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/2,31,33\">",
"     2,31,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the diagnosis of parathyroid carcinoma is made postoperatively, several authors recommend re-operation with ipsilateral thyroidectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/31,32,34\">",
"     31,32,34",
"    </a>",
"    ]. If a parathyroid tumor appears to be well-demarcated (not invading surrounding tissue), but is found on pathological examination to invade adjacent tissue, re-operation to remove all tumor tissue is recommended, because there are no pathologic criteria that distinguish a carcinoma that will follow an indolent course from one with a more aggressive course.",
"   </p>",
"   <p>",
"    Nonsurgical therapies for parathyroid carcinoma have had disappointing results (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Role of adjuvant therapy'",
"    </a>",
"    below). Therefore, surgical resection of distant metastases (bone and lung) has been performed in some circumstances, primarily to debulk tumor as palliation from the effects of hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The postoperative management of patients with parathyroid carcinoma should include close monitoring of the patient's serum calcium concentration. Patients in whom the tumor is completely removed may develop the \"hungry bone syndrome\" and therefore need large doses of intravenous calcium and oral calcitriol. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3287?source=see_link\">",
"     \"Hungry bone syndrome following parathyroidectomy\"",
"    </a>",
"    .) As the bones heal, the requirements for calcium and calcitriol decrease.",
"   </p>",
"   <p>",
"    Patients with recurrent or metastatic parathyroid carcinoma can also be treated surgically. Most recurrences occur within the neck [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/33\">",
"     33",
"    </a>",
"    ]. Resection of lesions in the neck, lungs, and liver will often result in significant palliation from hypercalcemia. However, these reoperations are associated with substantial morbidity. As an example, in one series of 18 patients who underwent 28 reoperations, complications, most commonly recurrent laryngeal nerve palsies, occurred in 9 of the 28 procedures (32 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/37\">",
"     37",
"    </a>",
"    ]. Preoperative localizing studies are recommended to minimize morbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ROLE OF ADJUVANT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both adjuvant chemotherapy and radiation therapy have had generally poor results for the treatment of parathyroid carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/38\">",
"     38",
"    </a>",
"    ]. Use of either should be considered only when a patient is not a candidate for surgery and hypercalcemia cannot be controlled [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/2,18,19\">",
"     2,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The experience with radiation therapy is limited to small observational studies. In general, radiation therapy has had disappointing results [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/1,38\">",
"     1,38",
"    </a>",
"    ]. However, in one series of six patients who received local radiation therapy after surgery, none had a recurrence after follow-up for an average of five years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/39\">",
"     39",
"    </a>",
"    ]. In a larger series of 26 patients with locally invasive disease followed for a mean of 7.9 years (range 2 to 21), only one of six patients who had adjuvant radiation therapy had a local relapse, compared with 10 of 20 who had not received radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/21\">",
"     21",
"    </a>",
"    ]. In a series from the Mayo Clinic, all four patients treated with surgery and adjuvant radiation therapy with doses of 66 to 70 Gy had no recurrence at 60 months of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/40\">",
"     40",
"    </a>",
"    ]. There is one report of long-term (11-year) survival of a patient with invasive parathyroid carcinoma treated with radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the rarity of parathyroid carcinoma, adjuvant chemotherapy has been difficult to evaluate systematically. Various agents, either alone or in combination have resulted in rare responses [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/38\">",
"     38",
"    </a>",
"    ]. One patient with pulmonary metastases responded to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    , 5-fluorouracil, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    with normalization of serum calcium for 13 months [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/38\">",
"     38",
"    </a>",
"    ], while another with recurrent disease responded to dacarbazine alone with a two-month normalization of serum calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H476261\">",
"    <span class=\"h2\">",
"     Biotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biologic agents based on gene products such as parafibromin, an inhibitor of cell proliferation in parathyroid neoplasia, telomerase inhibitors such as azidothymidine, and immune therapy constitute novel emerging therapies with encouraging in-vitro results, and may prove useful clinically in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MEDICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the tumor is no longer amenable to surgical intervention, treatment becomes limited to the control of hypercalcemia with hydration, a calcimimetic agent or intravenous bisphosphonate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Calcimimetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;One available approach is administration of a calcimimetic drug that reduces PTH secretion by increasing the sensitivity of the calcium-sensing receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"     Cinacalcet",
"    </a>",
"    , Sensipar, a longer-acting calcimimetic drug, is available for the treatment of hypercalcemia in parathyroid cancer, for secondary hyperparathyroidism associated with renal failure, and for the treatment of severe hypercalcemia in patients with primary hyperparathyroidism unable to undergo parathyroidectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link&amp;anchor=H25#H25\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\", section on 'Calcimimetics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link&amp;anchor=H20#H20\">",
"     \"Management of primary hyperparathyroidism\", section on 'Calcimimetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a 16-week open-label study of 29 patients with inoperable parathyroid carcinoma,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    (dose titrated to achieve calcium &le;10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or up to 90 mg four times daily) successfully reduced serum calcium concentration by at least 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in 62 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/43\">",
"     43",
"    </a>",
"    ]. Mean PTH levels decreased but not significantly. Adverse events (nausea, vomiting, headache, dehydration) were common and resulted in discontinuation in five patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     Pamidronate",
"    </a>",
"    , a drug approved by the United States Food and Drug Administration for hypercalcemia of malignancy, has been reported to improve hypercalcemia in individual cases of parathyroid carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. One would therefore predict that the bisphosphonate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    , which is approved for and is more potent than pamidronate in treating hypercalcemia of malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/46\">",
"     46",
"    </a>",
"    ], would also be effective for hypercalcemia due to parathyroid carcinoma, although this effect has not yet been documented. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     COURSE AND OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia is the principal cause of morbidity and mortality from parathyroid carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/2,18,19\">",
"     2,18,19",
"    </a>",
"    ]. The carcinomas grow very slowly in most patients, but can occasionally be aggressive [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/47\">",
"     47",
"    </a>",
"    ]. It appears that the disease typically follows one of three courses: one-third of patients are cured at initial or follow-up surgery, one-third recur after a prolonged disease-free survival but may be cured with reoperation, and one-third of patients experience a short and aggressive course [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted, the recurrence rate is high, even after seemingly successful surgery. In one study, as an example, among 22 patients who had normal serum calcium concentrations after surgery, the recurrence rates at 1, 5, and 10 years were 27, 82, and 91 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/19\">",
"     19",
"    </a>",
"    ]. In this and several other older studies, the combined 5- and 10-year survival rates varied from 50 to 70 and 13 to 35 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/2,18,19\">",
"     2,18,19",
"    </a>",
"    ], with a mean survival time of six to seven years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/2,18\">",
"     2,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, survival may be improving. The National Cancer Database survey (1985 to 1995) reported 5- and 10-year survival rates of 55.5 and 49 percent, respectively, in their series of 286 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/48\">",
"     48",
"    </a>",
"    ]. In a study using the SEER cancer registry (1988 to 2003), 5- and 10-year survival rates were 83.9 and 67.8 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/4\">",
"     4",
"    </a>",
"    ]. Similarly, in a series reporting on 27 patients, the survival at five years was 85 percent and at 10 years was 77 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/21\">",
"     21",
"    </a>",
"    ]. Young age, female gender, recent year of diagnosis, and absence of distant metastases were associated with improved survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     GENETIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of patients with sporadic parathyroid cancer have clinically unsuspected germline HRPT2 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/7\">",
"     7",
"    </a>",
"    ], and such mutations carry important implications for management of the patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    for early detection or prevention of parathyroid malignancy in family members [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, genetic testing for germline HRPT2 mutation is clinically appropriate in most patients with sporadic parathyroid carcinoma. Genetic HRPT2 testing is also indicated when parathyroid carcinoma occurs in a setting of known familial hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/9\">",
"     9",
"    </a>",
"    ], or when features suggestive of HPT-JT are present in the index patient. It is not known whether germline HRPT2 testing may be indicated in patients with sporadic \"atypical\" parathyroid adenomas, which exhibit clinical or pathological features suggestive of carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. There is no role for HRPT2 germline testing in patients with typical sporadic parathyroid adenomas.",
"   </p>",
"   <p>",
"    Genetic diagnosis of a germline HRPT2 inactivating mutation indicates that such a patient may have classic HPT-JT, expressing its initial manifestation, or phenotypic variants, such as familial isolated hyperparathyroidism, or a form of HPT-JT with altered penetrance of the component features. Pending additional data on variant syndromes ascertained in this fashion, one must conservatively assume they carry a similar risk of parathyroid cancer (15 percent), as is found in classic HPT-JT.",
"   </p>",
"   <p>",
"    The following are general principles and management guidelines only, not intended to supplant the need for endocrine and medical genetic evaluation of specific individuals and their families who are ascertained in this way.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     What if the HRPT2 genetic test shows a mutation?",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the proband (index patient) with apparently sporadic parathyroid cancer, management of the existing malignancy would typically not be altered by genetic diagnosis of HRPT2 mutation. However, this genetic diagnosis would mean that all parathyroid glands remain at increased risk for developing entirely new tumors, themselves potentially malignant. Thus, in several situations, such as recurrent HPT after seemingly successful surgery, or worsened hypercalcemia in the face of apparently stable metastatic tumor burden, knowledge of an HPRT2 mutation would caution against the assumption that the original tumor is entirely responsible, and could focus surgical attention on previously normal parathyroids in the neck or mediastinum.",
"   </p>",
"   <p>",
"    In addition, HRPT2 testing of the index patient with parathyroid cancer is indicated if there are family members who could benefit from the genetic diagnosis. If the index patient proves to have a detectable germline mutation, then relatives at risk can be definitely tested (also more rapidly and less expensively) for the presence or absence of that specific mutation. One major benefit of testing is the reassurance provided to relatives who prove to have not inherited the mutation, diminishing anxiety as well as ongoing costs of disease surveillance.",
"   </p>",
"   <p>",
"    For relatives who did inherit the mutation, their heightened risk of parathyroid malignancy mandates careful clinical attention, beginning with immediate biochemical testing for primary hyperparathyroidism followed by surgery for those whose biochemical screen is suggestive or diagnostic of primary hyperparathyroidism. For individuals who carry the HRPT2 mutation but have no evidence of hyperparathyroidism, a program of prospective surveillance is recommended. The optimal way to conduct such surveillance remains uncertain, and will be informed by ongoing clinical experience, emerging data on disease penetrance, and available therapies.",
"   </p>",
"   <p>",
"    For now, we think a reasonable approach would be measurement of serum calcium and PTH every six months, maintaining a high level of suspicion in interpreting results and a low threshold for proceeding to parathyroid surgery. The sensitivity of such screening may be enhanced by use of ionized calcium measurements, while specificity may be enhanced by maintenance of adequate vitamin D status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Surgical approach for HRPT2 mutation carriers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to initial parathyroid surgery in hyperparathyroid patients with known HRPT2 mutation should take into account the substantial malignant potential, tempered by the expectation from classic HPT-JT that most tumors will still be benign, together with the increased risk of multiglandular disease, asynchrony in tumor development, and the possibility that tumors might occasionally be nonfunctional.",
"   </p>",
"   <p>",
"    Therefore, we generally advise bilateral exploration be performed, identifying all parathyroid glands. Grossly abnormal or suspicious-appearing glands should be resected, bearing in mind the risk of malignancy. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Surgery'",
"    </a>",
"    above.) At this time, we think it is reasonable for the surgeon to leave in situ any normal-appearing glands, perhaps marking their location for possible future operations.",
"   </p>",
"   <p>",
"    Total parathyroidectomy has been advocated by some clinicians for HRPT2 mutation carriers with hyperparathyroidism. Currently we do not favor this approach because of the considerable morbidity associated with management of lifelong hypoparathyroidism, the significant but non-overwhelming penetrance of malignancy, and the expectation that prospective surveillance should identify tumors sufficiently early to prevent death from metastatic cancer. Prophylactic total parathyroidectomy could gain more support",
"    <span class=\"nowrap\">",
"     if/when",
"    </span>",
"    treatment modalities for hypoparathyroidism improved, eg, with availability of inexpensive and easily administered PTH replacement therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     What if HRPT2 genetic testing is negative?",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is a less helpful and less definitive result than a positive test would be, because even among families with classic HPT-JT about 40 percent have no detectable mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13688/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. Such families are likely to still have occult HRPT2 mutations, but which evade detection because only the coding region of the gene is generally sequenced, and inactivating mutations would be expected to occur in regulatory regions in some families.",
"   </p>",
"   <p>",
"    Therefore, a negative test does not provide strong reassurance that the index patient with sporadic parathyroid carcinoma is HRPT2 mutation-free. Under these circumstances the likelihood of a familial syndrome might gain clinical support by jaw, kidney, and uterine imaging. Overall, however, this uninformative genetic test result means that the patient and family may still be at risk for harboring an occult mutation and should be treated and followed accordingly. Genetic counseling to assess the diminished but not negligible level of risk may be especially helpful in this setting.",
"   </p>",
"   <p>",
"    How does one approach the patient with sporadic carcinoma for whom genetic testing will not or cannot be done, perhaps because of expense, personal choice, etc? Jaw and kidney imaging of the patient and family may provide helpful information, but all family members who might have inherited the proband's potentially mutant HRPT2 allele would be considered to be at risk, and in general be subjected to the surveillance as described above. Genetic counseling expertise is an essential component of the decision-making.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary hyperparathyroidism is usually caused by a parathyroid adenoma, occasionally by primary parathyroid hyperplasia, but only rarely by parathyroid carcinoma. Compared with patients with parathyroid adenomas, patients with parathyroid carcinomas are more likely to have symptoms, a neck mass, bone and kidney disease, marked hypercalcemia, and very high serum parathyroid hormone (PTH) concentrations. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The classic pathologic features of a trabecular pattern, mitotic figures, thick fibrous bands, capsular and vascular invasion, when present, are highly suggestive of parathyroid carcinoma, but definitive diagnosis depends on the presence of invasion into surrounding tissues or distant metastasis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery with en-bloc resection is the initial therapy, but when the tumor is no longer amenable to surgical intervention with intent to cure, treatment becomes focused on the control of hypercalcemia, eg, by medical therapy, which can include bisphosphonate or calcimimetic agents, or surgery to reduce tumor burden. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients with apparently sporadic parathyroid carcinoma have germline HRPT2 mutations, and genetic evaluation can play an important role in management of such patients and family members. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Genetic testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/1\">",
"      Wei CH, Harari A. Parathyroid carcinoma: update and guidelines for management. Curr Treat Options Oncol 2012; 13:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/2\">",
"      Obara T, Fujimoto Y. Diagnosis and treatment of patients with parathyroid carcinoma: an update and review. World J Surg 1991; 15:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/3\">",
"      Ruda JM, Hollenbeak CS, Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg 2005; 132:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/4\">",
"      Lee PK, Jarosek SL, Virnig BA, et al. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer 2007; 109:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/5\">",
"      Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 2002; 32:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/6\">",
"      Sharretts JM, Simonds WF. Clinical and molecular genetics of parathyroid neoplasms. Best Pract Res Clin Endocrinol Metab 2010; 24:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/7\">",
"      Shattuck TM, V&auml;lim&auml;ki S, Obara T, et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 2003; 349:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/8\">",
"      Howell VM, Haven CJ, Kahnoski K, et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet 2003; 40:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/9\">",
"      Simonds WF, Robbins CM, Agarwal SK, et al. Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 2004; 89:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/10\">",
"      Cetani F, Pardi E, Borsari S, et al. Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab 2004; 89:5583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/11\">",
"      Krebs LJ, Shattuck TM, Arnold A. HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab 2005; 90:5015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/12\">",
"      Rubin MR, Silverberg SJ. Editorial: HRPT2 in parathyroid cancer: a piece of the puzzle. J Clin Endocrinol Metab 2005; 90:5505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/13\">",
"      Tan MH, Morrison C, Wang P, et al. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res 2004; 10:6629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/14\">",
"      Cryns VL, Thor A, Xu HJ, et al. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med 1994; 330:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/15\">",
"      Cryns VL, Rubio MP, Thor AD, et al. p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab 1994; 78:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/16\">",
"      Shattuck TM, Kim TS, Costa J, et al. Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in parathyroid carcinoma. Clin Endocrinol (Oxf) 2003; 59:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/17\">",
"      Haven CJ, van Puijenbroek M, Tan MH, et al. Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas. Clin Endocrinol (Oxf) 2007; 67:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/18\">",
"      Shane E, Bilezikian JP. Parathyroid carcinoma: a review of 62 patients. Endocr Rev 1982; 3:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/19\">",
"      Wynne AG, van Heerden J, Carney JA, Fitzpatrick LA. Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine (Baltimore) 1992; 71:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/20\">",
"      Holmes EC, Morton DL, Ketcham AS. Parathyroid carcinoma: a collective review. Ann Surg 1969; 169:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/21\">",
"      Busaidy NL, Jimenez C, Habra MA, et al. Parathyroid carcinoma: a 22-year experience. Head Neck 2004; 26:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/22\">",
"      Owen RP, Silver CE, Pellitteri PK, et al. Parathyroid carcinoma: a review. Head Neck 2011; 33:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/23\">",
"      Wilkins BJ, Lewis JS Jr. Non-functional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery. Head Neck Pathol 2009; 3:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/24\">",
"      Robert JH, Trombetti A, Garcia A, et al. Primary hyperparathyroidism: can parathyroid carcinoma be anticipated on clinical and biochemical grounds? Report of nine cases and review of the literature. Ann Surg Oncol 2005; 12:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/25\">",
"      Messerer CL, Bugis SP, Baliski C, Wiseman SM. Normocalcemic parathyroid carcinoma: an unusual clinical presentation. World J Surg Oncol 2006; 4:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/26\">",
"      Fernandez-Ranvier GG, Jensen K, Khanafshar E, et al. Nonfunctioning parathyroid carcinoma: case report and review of literature. Endocr Pract 2007; 13:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/27\">",
"      Yamamoto T, Matsumura A. Comment on \"Clinical review 122: Parathyroid carcinoma\". J Clin Endocrinol Metab 2001; 86:5091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/28\">",
"      Sahasranam P, Tran MT, Mohamed H, Friedman TC. Multiglandular parathyroid carcinoma: a case report and brief review. South Med J 2007; 100:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/29\">",
"      Schantz A, Castleman B. Parathyroid carcinoma. A study of 70 cases. Cancer 1973; 31:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/30\">",
"      Bondeson L, Sandelin K, Grimelius L. Histopathological variables and DNA cytometry in parathyroid carcinoma. Am J Surg Pathol 1993; 17:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/31\">",
"      Wang CA, Gaz RD. Natural history of parathyroid carcinoma. Diagnosis, treatment, and results. Am J Surg 1985; 149:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/32\">",
"      Sandelin K, Thompson NW, Bondeson L. Metastatic parathyroid carcinoma: dilemmas in management. Surgery 1991; 110:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/33\">",
"      Sandelin K, Auer G, Bondeson L, et al. Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg 1992; 16:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/34\">",
"      Hoelting T, Weber T, Werner J, Herfarth C. Surgical treatment of parathyroid carcinoma (Review). Oncol Rep 2001; 8:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/35\">",
"      Flye MW, Brennan MF. Surgical resection of metastatic parathyroid carcinoma. Ann Surg 1981; 193:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/36\">",
"      Obara T, Okamoto T, Ito Y, et al. Surgical and medical management of patients with pulmonary metastasis from parathyroid carcinoma. Surgery 1993; 114:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/37\">",
"      Kebebew E, Arici C, Duh QY, Clark OH. Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg 2001; 136:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/38\">",
"      Shane E. Clinical review 122: Parathyroid carcinoma. J Clin Endocrinol Metab 2001; 86:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/39\">",
"      Chow E, Tsang RW, Brierley JD, Filice S. Parathyroid carcinoma--the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 1998; 41:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/40\">",
"      Munson ND, Foote RL, Northcutt RC, et al. Parathyroid carcinoma: is there a role for adjuvant radiation therapy? Cancer 2003; 98:2378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/41\">",
"      Calandra DB, Chejfec G, Foy BK, et al. Parathyroid carcinoma: biochemical and pathologic response to DTIC. Surgery 1984; 96:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/42\">",
"      Collins MT, Skarulis MC, Bilezikian JP, et al. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 1998; 83:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/43\">",
"      Silverberg SJ, Rubin MR, Faiman C, et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 2007; 92:3803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/44\">",
"      de Papp AE, Kinder B, LiVolsi V, et al. Parathyroid carcinoma arising from parathyroid hyperplasia: autoinfarction following intravenous treatment with pamidronate. Am J Med 1994; 97:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/45\">",
"      Newrick PG, Braatvedt GD, Webb AJ, et al. Prolonged remission of hypercalcaemia due to parathyroid carcinoma with pamidronate. Postgrad Med J 1994; 70:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/46\">",
"      Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/47\">",
"      Harari A, Waring A, Fernandez-Ranvier G, et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab 2011; 96:3679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13688/abstract/48\">",
"      Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1999; 86:538.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2042 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-B63444C5D6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_23_13688=[""].join("\n");
var outline_f13_23_13688=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MOLECULAR PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Atypical presentations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ROLE OF ADJUVANT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H476261\">",
"      Biotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Calcimimetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      COURSE AND OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      GENETIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      What if the HRPT2 genetic test shows a mutation?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Surgical approach for HRPT2 mutation carriers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      What if HRPT2 genetic testing is negative?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=related_link\">",
"      Clinical manifestations of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3287?source=related_link\">",
"      Hungry bone syndrome following parathyroidectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=related_link\">",
"      Management of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17174?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Definition and genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40387?source=related_link\">",
"      Parathyroid cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=related_link\">",
"      Parathyroid exploration for primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30361?source=related_link\">",
"      Pathogenesis and etiology of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18377?source=related_link\">",
"      Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_23_13689="Evaluation of bone marrow aspirate smears";
var content_f13_23_13689=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of bone marrow aspirate smears",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/23/13689/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/23/13689/contributors\">",
"     David S Rosenthal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/23/13689/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/23/13689/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/23/13689/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/23/13689/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/23/13689/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspiration and biopsy of the bone marrow is used to diagnose, confirm,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stage hematologic disease, and is a diagnostic tool in non-hematologic disorders (eg, storage disease, systemic infection) and malignancies. It is an ambulatory procedure performed under local anesthesia, with low morbidity. As an example, in a survey of the experience of members of the British Society of Hematology, covering over 54,000 procedures, there were only 26 reported adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13689/abstract/1\">",
"     1",
"    </a>",
"    ]. The most frequent complication was bleeding (14 patients), requiring transfusion in six instances, and resulting in one death. Pain at the site of the procedure is the second most common complication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5482?source=see_link&amp;anchor=H31#H31\">",
"     \"Bone marrow aspiration and biopsy: Indications and technique\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In adults, bone marrow aspiration can be performed from the sternum at the level of the second or third intercostal space, the anterior iliac crest, or the posterior iliac crest. Because of the greater depth of penetration required, bone marrow biopsies are usually carried out from the posterior iliac crest, in the region of the posterior superior iliac spine, a location which normally has a very high concentration of hematopoietically active bone marrow (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74577 \" href=\"UTD.htm?27/2/27682\">",
"     image 1",
"    </a>",
"    ). The technique of bone marrow aspiration and biopsy is also considered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5482?source=see_link\">",
"     \"Bone marrow aspiration and biopsy: Indications and technique\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation of bone marrow aspirate smears will be discussed here. Evaluation of the peripheral smear is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38313?source=see_link\">",
"     \"Evaluation of the peripheral blood smear\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEED FOR UNILATERAL VERSUS BILATERAL STUDY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow",
"    <span class=\"nowrap\">",
"     aspiration/biopsy",
"    </span>",
"    is often performed as part of the staging workup of patients with malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H29#H29\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Bone marrow examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29206?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial evaluation and diagnosis of Hodgkin lymphoma in adults\", section on 'Bone marrow biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To determine the utility of bilateral (versus unilateral) examination, a retrospective analysis of 1864 bilateral bone marrow biopsies was undertaken [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13689/abstract/2\">",
"     2",
"    </a>",
"    ]. Of these, 410 (22 percent) were involved with malignancy and 48 (2.6 percent) showed only unilateral involvement. The 48 cases of unilateral involvement were distributed as follows (total number of samples in parentheses):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hodgkin lymphoma (362) &mdash; 19",
"     </li>",
"     <li>",
"      Sarcoma (94) &mdash; 14",
"     </li>",
"     <li>",
"      Carcinoma (381) &mdash; 11",
"     </li>",
"     <li>",
"      non-Hodgkin lymphoma (883) &mdash; 4",
"     </li>",
"     <li>",
"      Multiple myeloma (56),",
"      <span class=\"nowrap\">",
"       leukemia/myelodysplasia",
"      </span>",
"      (53) &mdash; zero",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SAMPLE PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most difficult part of the procedure is the handling of the material; clinicians should check with the hematopathology laboratory prior to the procedure for clarification about slide preparation as well as the collection of additional specimens for cytogenetics, immunologic studies,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cultures. It is often helpful to have another person at the procedure to help make the aspirate smears before the sample forms a clot. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5482?source=see_link&amp;anchor=H22#H22\">",
"     \"Bone marrow aspiration and biopsy: Indications and technique\", section on 'Preparation of samples'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are many different techniques for preparing marrow aspirate smears in order to assure that there is adequate cellularity and good morphology. Most laboratories employ Wright-Giemsa staining to highlight nuclear and cytoplasmic characteristics.",
"   </p>",
"   <p>",
"    Aspirates are performed at either a sternal (less commonly) or iliac site (most commonly). If a biopsy is indicated, then the appropriate site is the posterior iliac crest. When both an aspirate and biopsy are performed together, the aspirate is completed first and the biopsy performed at a site a few millimeters removed from the aspiration site. A two-needle technique was found to be superior to a single",
"    <span class=\"nowrap\">",
"     needle/single",
"    </span>",
"    site technique, with the latter often resulting in a biopsy specimen denuded of marrow cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13689/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to the aspirate procedure, the indications for the test should be reviewed and the examiner should be ready to collect extra specimens for cytogenetic, immunologic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    culture studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5482?source=see_link&amp;anchor=H5#H5\">",
"     \"Bone marrow aspiration and biopsy: Indications and technique\", section on 'Advanced preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Procedure related pain and analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 75 percent of hematologic patients undergoing marrow aspiration and biopsy experience procedural pain, with one-third of these patients indicating severe pain [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13689/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children, general anesthesia for short duration has been shown to be safe and effective when carried out by trained professionals [",
"      <a class=\"abstract\" href=\"UTD.htm?13/23/13689/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In adults, a combination of oral analgesics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"       oxycodone",
"      </a>",
"      ) and anxiolytic agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      ) in addition to local anesthesia with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      hydrochloride (1 percent), may reduce the overall perception of pain levels [",
"      <a class=\"abstract\" href=\"UTD.htm?13/23/13689/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other methods, such as using",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"      nitrous oxide",
"     </a>",
"     /oxygen",
"    </span>",
"    50:50 plus a local anesthetic may also significantly reduce pain scores [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13689/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5482?source=see_link&amp;anchor=H8#H8\">",
"     \"Bone marrow aspiration and biopsy: Indications and technique\", section on 'Premedications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     The dry tap",
"    </span>",
"    &nbsp;&mdash;&nbsp;On occasion, marrow aspiration is not successful, resulting in what has been called a \"dry tap.\" There are a number of possible reasons for this; the most common cause is that the tip of the aspiration needle is not within the marrow cavity. Cautious advancement of the needle, or reinsertion into an adjacent site usually suffices if this is the problem.",
"   </p>",
"   <p>",
"    In other cases, the bone marrow cavity may have been entered, but little or no material can be aspirated, either because marrow cellularity is severely reduced (eg, aplastic anemia, bone marrow necrosis [see below]), or the bone marrow is intensely hypercellular (eg, leukemia, lymphoma) or fibrotic (eg, myelofibrosis, hairy cell leukemia), thus resisting attempts at aspiration.",
"   </p>",
"   <p>",
"    If a true dry tap occurs, bone marrow biopsy should be performed. Touch preparations can be made by rolling the biopsy specimen on glass slides. This will often result in sufficient additional material becoming available for diagnostic evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bone marrow necrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncommonly, aspiration of the bone marrow cavity at one or more sites may yield necrotic material with cells having indistinct cellular outlines and smudged nuclei, surrounded by amorphous eosinophilic material [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13689/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. The most common causes of this finding are bone marrow infarction during or following a vaso-occlusive crisis involving marrow-containing bone in sickle cell disease and marrow infiltration with malignant cells, often of hematopoietic origin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13689/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18506?source=see_link\">",
"     \"Bone and joint complications in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other causes include direct damage to bone (eg, radiation, trauma, decompression sickness, aseptic necrosis), infection (HIV, tuberculosis, paracoccidiomycosis, typhoid fever, septic shock), and lupus erythematosus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13689/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. Affected patients often complain of fever and bone pain [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13689/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Common laboratory findings include circulating nucleated red cells, thrombocytopenia, anemia, and elevated serum levels of lactate dehydrogenase and alkaline phosphatase [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13689/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gelatinous degeneration of the marrow with serous fat atrophy and varying degrees of cytopenia has been described in patients with anorexia nervosa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=see_link&amp;anchor=H31379427#H31379427\">",
"     \"Anorexia nervosa in adults and adolescents: Medical complications and their management\", section on 'Hematologic'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     LOW POWER EXAMINATION OF THE MARROW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow smears are first examined under low power magnification to look for the presence of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Adequacy of the sample (see",
"      <a class=\"local\" href=\"#H5\">",
"       'The dry tap'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Bone marrow necrosis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Presence or absence of cellular monotony",
"     </li>",
"     <li>",
"      Presence or absence of large cells, clumps of tumor cells, or storage cells",
"     </li>",
"     <li>",
"      Presence or absence of bone marrow spicules",
"     </li>",
"     <li>",
"      Ratio of fat to overall cellularity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example of the above, one might be struck by the monotony of the cell population, such as might be seen in a patient with acute lymphocytic leukemia (",
"    <a class=\"graphic graphic_picture graphicRef66656 \" href=\"UTD.htm?33/26/34216\">",
"     picture 1",
"    </a>",
"    ) or chronic prolymphocytic leukemia (",
"    <a class=\"graphic graphic_picture graphicRef70577 \" href=\"UTD.htm?42/12/43207\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4378004\">",
"    <span class=\"h2\">",
"     Large cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest cells one will normally see in a bone marrow aspirate are megakaryocytes, the immediate precursor of circulating platelets (",
"    <a class=\"graphic graphic_picture graphicRef55409 graphicRef50650 \" href=\"UTD.htm?41/4/42056\">",
"     picture 3A-B",
"    </a>",
"    ). Other large cells that are seen only under abnormal circumstances include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reed-Sternberg cells in patients with Hodgkin lymphoma (",
"      <a class=\"graphic graphic_picture graphicRef63379 \" href=\"UTD.htm?41/18/42276\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Giant, bizarre malignant plasma cells in multiple myeloma (",
"      <a class=\"graphic graphic_picture graphicRef72153 \" href=\"UTD.htm?27/45/28372\">",
"       picture 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Giant early red cell precursors (proerythroblasts) in acquired pure red cell aplasia as seen after infection with parvovirus B19 (",
"      <a class=\"graphic graphic_picture graphicRef51435 \" href=\"UTD.htm?26/42/27304\">",
"       picture 6",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4378011\">",
"    <span class=\"h2\">",
"     Cells in clumps or clusters",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appearance of large clumps of cells scattered about, often at the sides or end of the smear, with indistinct cellular borders, might turn out to be metastatic cancer. Such clumps may be relatively amorphous (",
"    <a class=\"graphic graphic_picture graphicRef70576 \" href=\"UTD.htm?2/11/2228\">",
"     picture 7",
"    </a>",
"    ) or might form rosette-like structures as in metastatic neuroblastoma (",
"    <a class=\"graphic graphic_picture graphicRef73187 \" href=\"UTD.htm?41/49/42768\">",
"     picture 8",
"    </a>",
"    ). One might also see clumps or sheets of malignant plasma cells in multiple myeloma (",
"    <a class=\"graphic graphic_picture graphicRef72153 \" href=\"UTD.htm?27/45/28372\">",
"     picture 5",
"    </a>",
"    ), or a benign finding such as a clump of osteoblasts (",
"    <a class=\"graphic graphic_picture graphicRef75668 \" href=\"UTD.htm?24/53/25429\">",
"     picture 9",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4378018\">",
"    <span class=\"h2\">",
"     Storage cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unusual clusters of large cells seen on low-power scanning may be storage cells, which on higher power may reveal the presence of macrophages with voluminous cytoplasm, containing undigested lipids. These may include the storage cell of Gaucher's Disease, a macrophage containing cerebrosides and creating a typical striated appearance to the cytoplasm (",
"    <a class=\"graphic graphic_picture graphicRef59255 \" href=\"UTD.htm?14/18/14630\">",
"     picture 10",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=see_link\">",
"     \"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    ) or Niemann-Pick cells, macrophages containing sphingomyelin, with a characteristic foamy appearance of the cytoplasm (",
"    <a class=\"graphic graphic_picture graphicRef75651 \" href=\"UTD.htm?16/63/17398\">",
"     picture 11",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=see_link&amp;anchor=H19#H19\">",
"     \"Hereditary neuropathies associated with generalized disorders\", section on 'Niemann-Pick disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Storage cells containing hexagonal, non-staining crystals may be seen in patients with the lysosomal storage disease cystinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13689/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12584?source=see_link\">",
"     \"Cystinosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4378025\">",
"    <span class=\"h2\">",
"     Macrophages with ingested cells or debris",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased numbers of otherwise normal-appearing macrophages which have ingested mature red cells, normoblasts, platelets,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neutrophils (",
"    <a class=\"graphic graphic_picture graphicRef81067 \" href=\"UTD.htm?17/30/17890\">",
"     picture 12",
"    </a>",
"    ) are seen in the hemophagocytic syndrome, often seen after viral infections, such as Epstein-Barr virus infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\", section on 'Hemophagocytic lymphohistiocytosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link\">",
"     \"Hemophagocytic lymphohistiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Normal-appearing macrophages may also contain debris-like material, such as ingested apoptotic tumor cells (ie, tingible body macrophages as seen in highly aggressive lymphomas), melanin-containing granules in a patient with melanoma metastatic to bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13689/abstract/21\">",
"     21",
"    </a>",
"    ], or crystals in patients with cystinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13689/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma\", section on 'Morphology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Estimation of cellularity and myeloid to erythroid ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;After a thorough scanning under low and intermediate power, one can estimate overall bone marrow cellularity, which should be in the range of 40 to 60 percent in normal adults, with a somewhat lower range in elderly patients. A rough guide to the normal decline in cellularity with age is given by the following:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; Bone marrow cellularity (%) &nbsp;&asymp; &nbsp;100 &nbsp;- &nbsp;age (years)",
"   </p>",
"   <p>",
"    Optimally, bone marrow cellularity is estimated from a bone marrow biopsy specimen (",
"    <a class=\"graphic graphic_picture graphicRef68384 \" href=\"UTD.htm?27/53/28500\">",
"     picture 13",
"    </a>",
"    ), but cellularity can often be estimated on an aspirate provided that it is performed in an area containing marrow spicules (",
"    <a class=\"graphic graphic_picture graphicRef63378 \" href=\"UTD.htm?37/47/38646\">",
"     picture 14",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Greater than 60 percent cellularity on the bone marrow biopsy suggests hypercellularity, while under 30 to 40 percent implies hypocellularity, as may be seen in idiopathic aplastic anemia (",
"    <a class=\"graphic graphic_picture graphicRef63867 \" href=\"UTD.htm?34/43/35513\">",
"     picture 15",
"    </a>",
"    ), in the hypocellular variant of myelodysplastic syndrome, or if the biopsy was performed in an area that had recently received high-dose radiation therapy.",
"   </p>",
"   <p>",
"    The myeloid to erythroid ratio (M:E ratio) can also be estimated under scanning power (",
"    <a class=\"graphic graphic_picture graphicRef51478 \" href=\"UTD.htm?39/42/40611\">",
"     picture 16",
"    </a>",
"    ); it is normal to observe approximately 3 to 4 cells of the myeloid line for every cell in the erythroid line (ie, a M:E ratio between 3:1 and 4:1).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The M:E ratio is typically increased in chronic myeloid leukemia, due to an absolute increase in cells of the granulocyte series (",
"      <a class=\"graphic graphic_picture graphicRef68724 \" href=\"UTD.htm?8/11/8375\">",
"       picture 17",
"      </a>",
"      ), and in pure red cell aplasia, due to an absolute decrease (or absence) of red cell precursors.",
"     </li>",
"     <li>",
"      The M:E ratio is most frequently decreased when erythroid hyperplasia is present, as seen in acute or chronic hemolysis (",
"      <a class=\"graphic graphic_picture graphicRef75057 \" href=\"UTD.htm?42/36/43589\">",
"       picture 18",
"      </a>",
"      ), or in the presence of drug-induced agranulocytosis, due to the specific loss of cells of the granulocyte series.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HIGH POWER EXAMINATION OF THE MARROW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal marrow aspirate shows a heterogeneous population of cells, with normal myeloid and erythroid maturation and a scattering of adult lymphocytes (",
"    <a class=\"graphic graphic_picture graphicRef51478 \" href=\"UTD.htm?39/42/40611\">",
"     picture 16",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The myeloid series (",
"    <a class=\"graphic graphic_figure graphicRef75855 \" href=\"UTD.htm?30/58/31651\">",
"     figure 1",
"    </a>",
"    ) normally matures from a myeloblast (",
"    <a class=\"graphic graphic_picture graphicRef74014 \" href=\"UTD.htm?37/11/38067\">",
"     picture 19",
"    </a>",
"    ) to promyelocyte (",
"    <a class=\"graphic graphic_picture graphicRef73480 \" href=\"UTD.htm?21/25/21908\">",
"     picture 20",
"    </a>",
"    ) to myelocyte (",
"    <a class=\"graphic graphic_picture graphicRef54089 \" href=\"UTD.htm?1/7/1138\">",
"     picture 21",
"    </a>",
"    ) to metamyelocyte (",
"    <a class=\"graphic graphic_picture graphicRef59197 \" href=\"UTD.htm?25/60/26563\">",
"     picture 22",
"    </a>",
"    ) to a band form (",
"    <a class=\"graphic graphic_picture graphicRef82140 \" href=\"UTD.htm?16/42/17060\">",
"     picture 23",
"    </a>",
"    ) and then an adult neutrophil (",
"    <a class=\"graphic graphic_picture graphicRef60666 \" href=\"UTD.htm?30/37/31316\">",
"     picture 24",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6185?source=see_link\">",
"     \"Normal neutrophil development and kinetics\"",
"    </a>",
"    .) At the blast level, the nuclear to cytoplasmic ratio is very high and the scant cytoplasm is deep blue. As the cells mature, the nuclear chromatin starts to condense and invaginate and the cytoplasm develops the granulation typical of a mature neutrophil.",
"   </p>",
"   <p>",
"    Erythroid cells mature from an erythroblast to a series of normoblasts referred to as basophilic, polychromatophilic, and orthochromic normoblasts (",
"    <a class=\"graphic graphic_picture graphicRef68933 \" href=\"UTD.htm?39/7/40050\">",
"     picture 25",
"    </a>",
"    ). As these cells become more mature, the nucleus condenses, and the cytoplasm gradually takes on the pinkish appearance of hemoglobin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=see_link\">",
"     \"Regulation of erythropoiesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the marrow with a normal M:E ratio of approximately 3-5:1, there can be the presence of myeloid hyperplasia (eg, high M:E ratio), as seen in chronic myeloid leukemia (",
"    <a class=\"graphic graphic_picture graphicRef68724 \" href=\"UTD.htm?8/11/8375\">",
"     picture 17",
"    </a>",
"    ) or erythroid hyperplasia (eg, low M:E ratio), as seen in hemolytic anemias (",
"    <a class=\"graphic graphic_picture graphicRef75057 \" href=\"UTD.htm?42/36/43589\">",
"     picture 18",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Megaloblastic changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deficiencies of vitamin B12 or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    result in varying degrees of pancytopenia (ie, anemia, neutropenia, and thrombocytopenia) along with a hypercellular marrow with maturation abnormalities in both the myeloid and erythroid series. Not only are these cells larger than normal, but there is more open chromatin in the nucleus, creating megaloblasts, giant band forms, and giant metamyelocytes (",
"    <a class=\"graphic graphic_picture graphicRef82203 \" href=\"UTD.htm?27/53/28502\">",
"     picture 26",
"    </a>",
"    ). There is also a lack of synchrony between the nuclear and cytoplasmic maturation (",
"    <a class=\"graphic graphic_picture graphicRef68005 \" href=\"UTD.htm?23/25/23955\">",
"     picture 27",
"    </a>",
"    ), resulting in cells that have a cytoplasm that is more mature-appearing than their nucleus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute or chronic leukemia is confirmed and classified via examination of the bone marrow. There is usually partial or almost total replacement of the cellular component of the marrow by immature or undifferentiated cells, which, according to the French, American, and British (FAB) classification standard, should exceed 30 percent of the total cellularity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13689/abstract/22\">",
"     22",
"    </a>",
"    ]. However, in 1999, the World Health Organization classification system recommended that the blast count for the diagnosis of acute myeloid leukemia should be reduced from 30 to 20 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Morphologic, cytochemical or immunophenotypic, and cytogenetic and molecular studies must be performed in every case of suspected leukemia. Information derived from these studies is important for the correct diagnosis, and also for the subclassification of the process. The selection of treatment modality and an accurate prognosis are strongly dependent upon information derived from these studies.",
"   </p>",
"   <p>",
"    Classification of the leukemias may use, in part, the FAB classification system (",
"    <a class=\"graphic graphic_table graphicRef63050 \" href=\"UTD.htm?15/48/16141\">",
"     table 1",
"    </a>",
"    ), which is represented in the following series of slides for acute lymphoblastic leukemia (ALL: L1 through L3) and acute myeloid leukemia (AML, also called acute non-lymphocytic leukemia, ANLL: M0 through M7).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Acute lymphoblastic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FAB classification of acute lymphoblastic leukemia consists of three subtypes, L1 through L3:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      L1 lymphoblasts are referred to as classical lymphoblasts with a high nuclear to cytoplasmic ratio, in many cells just a rim of deep blue cytoplasm and a nucleus with several distinct and often indistinct nucleoli (",
"      <a class=\"graphic graphic_picture graphicRef72835 \" href=\"UTD.htm?36/12/37062\">",
"       picture 28",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef57831 \" href=\"UTD.htm?24/53/25439\">",
"       picture 29",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      L2 lymphoblasts include the \"classical\" lymphoblasts but also cells with more abundant cytoplasm and often fissured or clefted nuclei (",
"      <a class=\"graphic graphic_picture graphicRef52878 \" href=\"UTD.htm?13/1/13332\">",
"       picture 30",
"      </a>",
"      ) and (",
"      <a class=\"graphic graphic_picture graphicRef65474 \" href=\"UTD.htm?41/54/42848\">",
"       picture 31",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      L3 lymphoblasts are very undifferentiated, containing large nucleoli and often vacuolated cytoplasm (",
"      <a class=\"graphic graphic_picture graphicRef77240 \" href=\"UTD.htm?23/17/23830\">",
"       picture 32",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 1999 WHO classification conference suggested that these FAB terms may no longer be relevant, since L1 or L2 morphology do not predict immunophenotype, genetic abnormalities, or clinical behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13689/abstract/23\">",
"     23",
"    </a>",
"    ]. It also suggested that L3 morphology is generally equivalent to Burkitt lymphoma in leukemic phase, and should be diagnosed as such (",
"    <a class=\"graphic graphic_picture graphicRef57366 \" href=\"UTD.htm?38/38/39524\">",
"     picture 33",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Acute myeloid leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FAB classification of acute myeloid leukemia (AML) consists of eight major subtypes, M0 through M7 (",
"    <a class=\"graphic graphic_table graphicRef63050 \" href=\"UTD.htm?15/48/16141\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      M0 blast cells (",
"      <a class=\"graphic graphic_picture graphicRef80658 \" href=\"UTD.htm?41/61/42961\">",
"       picture 34",
"      </a>",
"      ) resemble FAB L2 blasts. They lack differentiating features and do not demonstrate either cytoplasmic granules or Auer rods, although they do express myeloid antigens.",
"     </li>",
"     <li>",
"      M1 blast cells (",
"      <a class=\"graphic graphic_picture graphicRef59431 \" href=\"UTD.htm?41/11/42163\">",
"       picture 35",
"      </a>",
"      ) are large cells with a high nuclear:cytoplasmic ratio with grayish blue cytoplasm, no granules, and a nucleus containing one to two distinct nucleoli.",
"     </li>",
"     <li>",
"      M2 blast cells (",
"      <a class=\"graphic graphic_picture graphicRef72214 \" href=\"UTD.htm?39/22/40291\">",
"       picture 36",
"      </a>",
"      ) are slightly more mature than M1 blasts; many of the cells contain granules and occasionally Auer rods can be noted, which are rod-like structures made up of coalesced granules or lysosomal material (",
"      <a class=\"graphic graphic_picture graphicRef52270 \" href=\"UTD.htm?27/48/28419\">",
"       picture 37",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      M3 blast cells (",
"      <a class=\"graphic graphic_picture graphicRef61002 \" href=\"UTD.htm?14/11/14517\">",
"       picture 38",
"      </a>",
"      ) are even more differentiated, often referred to as acute promyelocytic leukemia (APL). In this variant, the granules may be so pronounced that they almost obscure the nuclear cytoplasmic borders. Occasionally, these cells contain bundles of Auer rods, the so-called \"faggot cells\" (",
"      <a class=\"graphic graphic_picture graphicRef73965 \" href=\"UTD.htm?32/41/33424\">",
"       picture 39",
"      </a>",
"      ). Another variant within the M3 classification includes the microgranular type, in which the granules are not as apparent (",
"      <a class=\"graphic graphic_picture graphicRef61151 \" href=\"UTD.htm?14/37/14929\">",
"       picture 40",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      M4 AML, also called acute myelomonocytic leukemia (AMML) is usually an admixture of myeloblasts, promyelocytes, monoblasts and promonocytes (",
"      <a class=\"graphic graphic_picture graphicRef58646 \" href=\"UTD.htm?17/14/17633\">",
"       picture 41",
"      </a>",
"      ). A variant with increased marrow eosinophils (FAB classification M4EO) and an associated inv(16) chromosome abnormality has also been described (",
"      <a class=\"graphic graphic_picture graphicRef71045 \" href=\"UTD.htm?18/62/19424\">",
"       picture 42",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      M5 AML, also called acute monoblastic leukemia (AMoL) has oval and indented nuclei containing opaque cytoplasm and fine granules. There are two major variants of M5 AMoL, those without maturation (M5A) (",
"      <a class=\"graphic graphic_picture graphicRef51084 \" href=\"UTD.htm?27/39/28273\">",
"       picture 43",
"      </a>",
"      ) and with maturation to more mature cells of the monocytic series (M5B) (",
"      <a class=\"graphic graphic_picture graphicRef76635 \" href=\"UTD.htm?24/27/25010\">",
"       picture 44",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      M6 AML, also referred to as acute erythroid leukemia, erythroleukemia, or DiGuglielmo's disease, is made up of abnormal erythroblasts with features of nuclear pulverization, gigantism and multinucleated cells, admixed with myeloblasts (",
"      <a class=\"graphic graphic_picture graphicRef52638 \" href=\"UTD.htm?32/5/32849\">",
"       picture 45",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      M7 AML, also referred to as acute megakaryocytic leukemia, is made up of abnormal blasts which may often take on the appearance of L2, M0, or M1 blasts. They are differentiated from the others by virtue of either maturation to cells resembling normal megakaryocytes, as in the left panel (",
"      <a class=\"graphic graphic_picture graphicRef65416 \" href=\"UTD.htm?38/9/39058\">",
"       picture 46",
"      </a>",
"      ), or by special staining for the products of megakaryocytes, such as von Willebrand factor or platelet type glycoproteins, as in the right panel (",
"      <a class=\"graphic graphic_picture graphicRef65416 \" href=\"UTD.htm?38/9/39058\">",
"       picture 46",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Chronic lymphocytic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bone marrow smear in patients with chronic lymphocytic leukemia (CLL) and its variant chronic prolymphocytic leukemia is hypercellular with monotonous areas of small round cells containing a thin rim of cytoplasm (",
"    <a class=\"graphic graphic_picture graphicRef70577 \" href=\"UTD.htm?42/12/43207\">",
"     picture 2",
"    </a>",
"    ). On higher power the lymphocytes can be clearly distinguished from erythroid precursors (",
"    <a class=\"graphic graphic_picture graphicRef72694 \" href=\"UTD.htm?1/20/1350\">",
"     picture 47",
"    </a>",
"    ), with the mature lymphocytes of CLL being small round cells with pyknotic nuclei and scant blue cytoplasm, whereas the most mature normoblasts have a more clumped nuclear chromatin along with a greater amount of cytoplasm which is either bluish-red (polychromatophilic normoblast) or reddish (orthochromatic normoblast). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CLL and the indolent lymphoma, small lymphocytic lymphoma, are considered by the WHO classification scheme to be the same disease in different stages [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13689/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18887?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of small lymphocytic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Chronic myeloid leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bone marrow in chronic myeloid leukemia (CML) is most often hypercellular, with a markedly increased M:E ratio due to an absolute increase in cells of the myeloid series. The most abundant cells are usually myelocytes, metamyelocytes, and mature neutrophils, with myeloblasts usually representing &lt;5 percent of all cells of the myeloid series (",
"    <a class=\"graphic graphic_picture graphicRef68724 \" href=\"UTD.htm?8/11/8375\">",
"     picture 17",
"    </a>",
"    ). Auer rods are not seen unless the disease has transformed into an acute myeloid leukemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19609?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Myelodysplastic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The myelodysplastic syndrome (MDS) often presents clinically in a fashion similar to that of the acute leukemias, with laboratory findings of anemia, thrombocytopenia, and neutropenia. Associated findings on the peripheral smear may include varying degrees of macrocytosis of the circulating red cells, monocytosis, and dysplastic changes in the circulating granulocytes (eg, acquired pseudo-Pelger Huett changes) (",
"    <a class=\"graphic graphic_picture graphicRef71990 \" href=\"UTD.htm?4/45/4816\">",
"     picture 48",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In MDS, bone marrow smears reveal erythroid immaturity with nuclear-cytoplasmic disynchrony. In addition, there may be abnormal myeloid maturation with increased immaturity, and mature forms with decreased lobes (Pelger-Huet cells) and abnormal, poorly lobulated micro-megakaryocytes (",
"    <a class=\"graphic graphic_picture graphicRef59897 \" href=\"UTD.htm?14/52/15173\">",
"     picture 49",
"    </a>",
"    ). Iron staining of the marrow aspirate may also show the presence of erythroid precursors containing many iron-containing granules, often completely surrounding the nucleus (ring sideroblasts) (",
"    <a class=\"graphic graphic_picture graphicRef65887 \" href=\"UTD.htm?0/44/705\">",
"     picture 50",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Multiple myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple myeloma typically presents in the bone marrow with sheets of abnormal plasma cells, which may vary from immature plasmablasts and proplasmacytes to more mature plasma cells with an eccentrically-placed nucleus and a spokewheel pattern of their nuclear chromatin (",
"    <a class=\"graphic graphic_picture graphicRef61145 \" href=\"UTD.htm?33/12/33990\">",
"     picture 51",
"    </a>",
"    ). Occasionally there are \"flame\" cells, myeloma cells containing a pink \"flame like\" cytoplasm, usually associated with the production of a myeloma protein of the IgA class (",
"    <a class=\"graphic graphic_picture graphicRef72153 \" href=\"UTD.htm?27/45/28372\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, multiple myeloma may present with spotty areas of marrow involvement, such that aspirate smears from one marrow site may be normal, while others taken from the same or distant sites may be infiltrated with malignant cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H25#H25\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Waldenstrom macroglobulinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Waldenstrom macroglobulinemia (WM) is suspected in patients presenting with an IgM monoclonal spike on serum protein electrophoresis, often with signs and symptoms of hyperviscosity and the presence of anemia. The marrow is infiltrated by cells which have been termed plasmacytic lymphocytes (\"plymphocytes\") or lymphoplasmacytic cells, resembling a cross between a mature plasma cell and a small lymphocyte (",
"    <a class=\"graphic graphic_picture graphicRef66365 \" href=\"UTD.htm?28/2/28708\">",
"     picture 52",
"    </a>",
"    ). The abnormal cell in WM is a member of the lymphocytic series, but has more cytoplasm than a normal small lymphocyte, giving the cell a slightly eccentric nucleus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Primary myelofibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary (idiopathic) myelofibrosis is suspected in patients presenting with an enlarged spleen, varying degrees of anemia, teardrop-shaped red cells (",
"    <a class=\"graphic graphic_picture graphicRef55274 \" href=\"UTD.htm?42/37/43606\">",
"     picture 53",
"    </a>",
"    ) and a leukoerythroblastic blood smear (",
"    <a class=\"graphic graphic_picture graphicRef68110 \" href=\"UTD.htm?29/43/30390\">",
"     picture 54",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38313?source=see_link&amp;anchor=H36#H36\">",
"     \"Evaluation of the peripheral blood smear\", section on 'Leukoerythroblastic smear'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bone marrow aspiration in this disorder often results in a \"dry tap\", due to the presence of extensive infiltration of the marrow with mature and immature collagen and fibrous tissue, which is usually only demonstrated on bone marrow biopsy (",
"    <a class=\"graphic graphic_picture graphicRef57384 \" href=\"UTD.htm?17/34/17961\">",
"     picture 55",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef69139 \" href=\"UTD.htm?24/19/24886\">",
"     picture 56",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=see_link\">",
"     \"Clinical manifestations and diagnosis of primary myelofibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Essential thrombocythemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Essential thrombocythemia, also called primary or idiopathic thrombocytosis, is suspected in a patient with a markedly elevated platelet count (",
"    <a class=\"graphic graphic_picture graphicRef61742 \" href=\"UTD.htm?22/0/22536\">",
"     picture 57",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef68024 \" href=\"UTD.htm?20/49/21265\">",
"     picture 58",
"    </a>",
"    ), and varying degrees of bleeding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombosis. The bone marrow is most often normocellular, in contrast to polycythemia vera, in which the bone marrow is hypercellular. There are no bone marrow findings pathognomonic for this disorder, although megakaryocytic hyperplasia with or without clusters of mature or immature megakaryocytes is a common finding (",
"    <a class=\"graphic graphic_picture graphicRef67362 \" href=\"UTD.htm?24/34/25127\">",
"     picture 59",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18890?source=see_link\">",
"     \"Diagnosis and clinical manifestations of essential thrombocythemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14329441\">",
"    <span class=\"h2\">",
"     Systemic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic infection is often suspected in patients with unexplained fever, organomegaly,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lymphadenopathy. Staining of bone marrow aspirates for infectious bacterial, fungal, or viral agents is often helpful in establishing the diagnosis (",
"    <a class=\"graphic graphic_picture graphicRef52344 \" href=\"UTD.htm?16/40/17029\">",
"     picture 60",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef56193 \" href=\"UTD.htm?2/23/2419\">",
"     picture 61",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31927?source=see_link&amp;anchor=H20#H20\">",
"     \"Approach to the adult with fever of unknown origin\", section on 'Biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspiration and biopsy of the bone marrow is used to diagnose, confirm,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stage hematologic disease, and it is a diagnostic tool in non-hematologic disorders and malignancies. It is an ambulatory procedure easily performed under local anesthesia, with low morbidity. Indications and techniques for performing this procedure are discussed in depth elsewhere in UpToDate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5482?source=see_link\">",
"     \"Bone marrow aspiration and biopsy: Indications and technique\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Low power examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low power examination of the bone marrow allows one to evaluate the adequacy of the sample and the presence of bone marrow spicules, cellular monotony, large cells, clumps of tumor cells, or storage cells and the ratio of fat to overall cellularity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Presence of large cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normally, the largest cell seen in the bone marrow is the megakaryocyte, the cell responsible for platelet production. The presence of other large cells is an abnormal finding, and may indicate the presence of disease (eg, Hodgkin lymphoma, parvovirus infection, metastatic malignancy, storage disease). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Low power examination of the marrow'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     High power examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the bone marrow under high power allows one to determine overall cellularity, the ratio of cells of the myeloid line to the erythroid line, the maturation sequences of the major cellular elements, and the presence of abnormal cells. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'High power examination of the marrow'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Special stains may be employed to determine clonality (eg, immunoglobulin light chains), presence of reticulin or collagen (eg, silver and trichrome stains), presence of amyloid (eg, Congo red staining), as well as staining for the presence of various infectious agents.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13689/abstract/1\">",
"      Bain BJ. Bone marrow biopsy morbidity and mortality. Br J Haematol 2003; 121:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13689/abstract/2\">",
"      Wang J, Weiss LM, Chang KL, et al. Diagnostic utility of bilateral bone marrow examination: significance of morphologic and ancillary technique study in malignancy. Cancer 2002; 94:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13689/abstract/3\">",
"      Islam A. Bone marrow aspiration before bone marrow core biopsy using the same bone marrow biopsy needle: a good or bad practice? J Clin Pathol 2007; 60:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13689/abstract/4\">",
"      Lid&eacute;n Y, Landgren O, Arn&eacute;r S, et al. Procedure-related pain among adult patients with hematologic malignancies. Acta Anaesthesiol Scand 2009; 53:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13689/abstract/5\">",
"      Kuivalainen AM, Niemi-Murola L, Widenius T, et al. Comparison of articaine and lidocaine for infiltration anaesthesia in patients undergoing bone marrow aspiration and biopsy. Eur J Pain 2010; 14:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13689/abstract/6\">",
"      Meneses CF, de Freitas JC, Castro CG Jr, et al. Safety of general anesthesia for lumbar puncture and bone marrow aspirate/biopsy in pediatric oncology patients. J Pediatr Hematol Oncol 2009; 31:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13689/abstract/7\">",
"      Talamo G, Liao J, Bayerl MG, et al. Oral administration of analgesia and anxiolysis for pain associated with bone marrow biopsy. Support Care Cancer 2010; 18:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13689/abstract/8\">",
"      Johnson H, Burke D, Plews C, et al. Improving the patient's experience of a bone marrow biopsy - an RCT. J Clin Nurs 2008; 17:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13689/abstract/9\">",
"      Leyssen MH, Verwilghen RL. Diagnosis of bone marrow necrosis. Clin Lab Haematol 1979; 1:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13689/abstract/10\">",
"      Kiraly JF 3rd, Wheby MS. Bone marrow necrosis. Am J Med 1976; 60:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13689/abstract/11\">",
"      Brittin GM, Brecher G. Appearance of bone marrow smears with necrotic tumor cells. Blood 1971; 38:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13689/abstract/12\">",
"      Paydas S, Ergin M, Baslamisli F, et al. Bone marrow necrosis: clinicopathologic analysis of 20 cases and review of the literature. Am J Hematol 2002; 70:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13689/abstract/13\">",
"      Hamidou M, Rigal-Huguet F, Moreau A, et al. [Bone marrow necrosis in malignant hemopathies. 7 cases]. Rev Med Interne 1993; 14:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13689/abstract/14\">",
"      Dunn P, Shih LY, Liaw SJ, Sun CF. Bone marrow necrosis in 38 adult cancer patients. J Formos Med Assoc 1993; 92:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13689/abstract/15\">",
"      Miyoshi I, Daibata M, Ohtsuki Y, Taguchi H. Bone marrow necrosis. Br J Haematol 2005; 130:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13689/abstract/16\">",
"      Pereira RM, Velloso ER, Menezes Y, et al. Bone marrow findings in systemic lupus erythematosus patients with peripheral cytopenias. Clin Rheumatol 1998; 17:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13689/abstract/17\">",
"      Bulvik S, Aronson I, Ress S, Jacobs P. Extensive bone marrow necrosis associated with antiphospholipid antibodies. Am J Med 1995; 98:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13689/abstract/18\">",
"      Voulgarelis M, Giannouli S, Tasidou A, et al. Bone marrow histological findings in systemic lupus erythematosus with hematologic abnormalities: a clinicopathological study. Am J Hematol 2006; 81:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13689/abstract/19\">",
"      Resende LS, Mendes RP, Bacchi MM, et al. Bone marrow necrosis related to paracoccidioidomycosis: the first eight cases identified at autopsy. Histopathology 2009; 54:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13689/abstract/20\">",
"      Abdulsalam AH, Khamis MH, Bain BJ. Diagnosis of cystinosis from a bone marrow aspirate. Am J Hematol 2013; 88:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13689/abstract/21\">",
"      Serrier C, Lesesve JF. Metastatic malignant melanoma in the bone marrow. Blood 2013; 121:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13689/abstract/22\">",
"      Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13689/abstract/23\">",
"      Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4434 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-0D05C0E861-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_23_13689=[""].join("\n");
var outline_f13_23_13689=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEED FOR UNILATERAL VERSUS BILATERAL STUDY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SAMPLE PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Procedure related pain and analgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      The dry tap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bone marrow necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      LOW POWER EXAMINATION OF THE MARROW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4378004\">",
"      Large cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4378011\">",
"      Cells in clumps or clusters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4378018\">",
"      Storage cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4378025\">",
"      Macrophages with ingested cells or debris",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Estimation of cellularity and myeloid to erythroid ratio",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HIGH POWER EXAMINATION OF THE MARROW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Megaloblastic changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Leukemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Waldenstrom macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14329441\">",
"      Systemic infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Low power examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Presence of large cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      High power examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4434\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4434|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/2/27682\" title=\"diagnostic image 1\">",
"      Red marrow normal adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4434|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/58/31651\" title=\"figure 1\">",
"      PMN development and kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4434|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/26/34216\" title=\"picture 1\">",
"      ALL monotonous view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/12/43207\" title=\"picture 2\">",
"      Prolymph leukemia marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/12/20675\" title=\"picture 3A\">",
"      Megakaryocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/8/28804\" title=\"picture 3B\">",
"      Bone marrow megakaryocyte",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/18/42276\" title=\"picture 4\">",
"      Reed Sternberg cell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/45/28372\" title=\"picture 5\">",
"      Flame cell myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/42/27304\" title=\"picture 6\">",
"      Giant proerythroblast in PRCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/11/2228\" title=\"picture 7\">",
"      Metastatic cancer marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/49/42768\" title=\"picture 8\">",
"      Neuroblastoma in marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/53/25429\" title=\"picture 9\">",
"      Osteoblasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/18/14630\" title=\"picture 10\">",
"      Gaucher cells in marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/63/17398\" title=\"picture 11\">",
"      Niemann Pick cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/30/17890\" title=\"picture 12\">",
"      Hemophagocytic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/53/28500\" title=\"picture 13\">",
"      Normal bone marrow Low",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/47/38646\" title=\"picture 14\">",
"      Hypocellular marrow aspirate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/43/35513\" title=\"picture 15\">",
"      Aplastic anemia bone marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/42/40611\" title=\"picture 16\">",
"      Normal marrow aspirate low",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/11/8375\" title=\"picture 17\">",
"      CML marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/36/43589\" title=\"picture 18\">",
"      Erythroid hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/11/38067\" title=\"picture 19\">",
"      Normal human myeloblast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/25/21908\" title=\"picture 20\">",
"      Normal human promyelocyte",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/7/1138\" title=\"picture 21\">",
"      Normal human myelocyte",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/60/26563\" title=\"picture 22\">",
"      Normal human metamyelocyte",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/42/17060\" title=\"picture 23\">",
"      Normal human band form",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/37/31316\" title=\"picture 24\">",
"      Normal human PMN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/7/40050\" title=\"picture 25\">",
"      Erythroid precursors marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/53/28502\" title=\"picture 26\">",
"      Megaloblastic marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/25/23955\" title=\"picture 27\">",
"      Megaloblastic erythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/12/37062\" title=\"picture 28\">",
"      L1 lymphoblasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/53/25439\" title=\"picture 29\">",
"      Lymphoblasts FAB L1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/1/13332\" title=\"picture 30\">",
"      L2 lymphoblasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/54/42848\" title=\"picture 31\">",
"      Lymphoblasts FAB L2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/17/23830\" title=\"picture 32\">",
"      Lymphoblasts FAB L3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/38/39524\" title=\"picture 33\">",
"      Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/61/42961\" title=\"picture 34\">",
"      AML FAB M0",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/11/42163\" title=\"picture 35\">",
"      ANLL FAB M1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/22/40291\" title=\"picture 36\">",
"      ANLL FAB M2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/48/28419\" title=\"picture 37\">",
"      ANLL FAB M2 Auer rod",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/11/14517\" title=\"picture 38\">",
"      ANLL FAB M3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/41/33424\" title=\"picture 39\">",
"      AML FAB M3 Faggot cell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/37/14929\" title=\"picture 40\">",
"      AML FAB M3V Microgran",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/14/17633\" title=\"picture 41\">",
"      AML FAB M4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/62/19424\" title=\"picture 42\">",
"      AML FAB M4EO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/39/28273\" title=\"picture 43\">",
"      AML FAB M5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/27/25010\" title=\"picture 44\">",
"      AML FAB M5B maturation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/5/32849\" title=\"picture 45\">",
"      AML FAB M6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/9/39058\" title=\"picture 46\">",
"      AML FAB M7",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/20/1350\" title=\"picture 47\">",
"      CLL and AIHA marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/45/4816\" title=\"picture 48\">",
"      Pelger Huet anomaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/52/15173\" title=\"picture 49\">",
"      MDS abnormal megakaryocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/44/705\" title=\"picture 50\">",
"      Ring sideroblasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/12/33990\" title=\"picture 51\">",
"      Multiple myeloma marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/2/28708\" title=\"picture 52\">",
"      Lymphoplasmacytic cells in WM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/37/43606\" title=\"picture 53\">",
"      Tear drop cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/43/30390\" title=\"picture 54\">",
"      Leukoerythroblastic blood smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/34/17961\" title=\"picture 55\">",
"      Myelofibrosis bone marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/19/24886\" title=\"picture 56\">",
"      Myelofibrosis marrow collagen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/0/22536\" title=\"picture 57\">",
"      Essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/49/21265\" title=\"picture 58\">",
"      Manual hematocrit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/34/25127\" title=\"picture 59\">",
"      Ess thrombocythemia marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/40/17029\" title=\"picture 60\">",
"      Leish bone marrow biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/23/2419\" title=\"picture 61\">",
"      Disseminated histo bone marrow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4434|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/48/16141\" title=\"table 1\">",
"      FAB classification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=related_link\">",
"      Anorexia nervosa in adults and adolescents: Medical complications and their management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31927?source=related_link\">",
"      Approach to the adult with fever of unknown origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18506?source=related_link\">",
"      Bone and joint complications in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5482?source=related_link\">",
"      Bone marrow aspiration and biopsy: Indications and technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19609?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=related_link\">",
"      Clinical manifestations and diagnosis of primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18887?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of small lymphocytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12584?source=related_link\">",
"      Cystinosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18890?source=related_link\">",
"      Diagnosis and clinical manifestations of essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38313?source=related_link\">",
"      Evaluation of the peripheral blood smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=related_link\">",
"      Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=related_link\">",
"      Hereditary neuropathies associated with generalized disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29206?source=related_link\">",
"      Initial evaluation and diagnosis of Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6185?source=related_link\">",
"      Normal neutrophil development and kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=related_link\">",
"      Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=related_link\">",
"      Regulation of erythropoiesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_23_13690="Treatment and prognosis of basal cell carcinoma";
var content_f13_23_13690=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of basal cell carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/23/13690/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/23/13690/contributors\">",
"     Timothy K Chartier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/23/13690/contributors\">",
"     Sumaira Z Aasi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/23/13690/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/23/13690/contributors\">",
"     Robert S Stern, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/23/13690/contributors\">",
"     June K Robinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/23/13690/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/23/13690/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/23/13690/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basal cell carcinoma (BCC) is a common skin cancer that arises from the basal layer of epidermis and its appendages (",
"    <a class=\"graphic graphic_picture graphicRef57990 graphicRef65704 \" href=\"UTD.htm?35/45/36568\">",
"     picture 1A-B",
"    </a>",
"    ). Treatment of BCC is indicated due to the locally invasive, aggressive, and destructive effects of this tumor on skin and surrounding tissues (",
"    <a class=\"graphic graphic_picture graphicRef68274 graphicRef81632 \" href=\"UTD.htm?6/30/6632\">",
"     picture 2A-B",
"    </a>",
"    ). Effective therapies for BCC include electrodesiccation and curettage (ED&amp;C), surgical excision, Mohs micrographic surgery, topical and intralesional agents, radiation therapy, and photodynamic therapy (",
"    <a class=\"graphic graphic_table graphicRef70043 graphicRef56173 \" href=\"UTD.htm?38/5/39005\">",
"     table 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Tumor characteristics such as size, location, and pathology influence the selection of treatment. Treatments that are highly efficacious for BCCs without aggressive clinical or pathological features may be less likely to cure more aggressive lesions. Factors such as treatment tolerability, cost, and patient preference also guide the selection of an appropriate therapy.",
"   </p>",
"   <p>",
"    The treatment of BCCs without aggressive clinical or pathological features and the prognosis of BCC will be reviewed here. The treatment of BCCs with a high risk for recurrence, the epidemiology and diagnosis of BCC, and the options for systemic therapy in locally advanced or metastatic BCC are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=see_link\">",
"     \"Treatment of basal cell carcinomas at high risk for recurrence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=see_link\">",
"     \"Epidemiology and clinical features of basal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15063?source=see_link\">",
"     \"Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14293?source=see_link\">",
"     \"Systemic treatment of advanced cutaneous squamous and basal cell carcinomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20396140\">",
"    <span class=\"h2\">",
"     Tumor characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk for lesion recurrence influences the approach to treatment. BCCs that lack aggressive clinical or pathological features are less likely to recur than lesions with more aggressive features. Overly aggressive management of BCCs at low risk for recurrence may result in unnecessary inconveniences to the patient and increased cost to the medical system. Conversely, inadequate treatment of lesions with aggressive features can lead to subsequent tumor recurrence with potentially devastating consequences (",
"    <a class=\"graphic graphic_picture graphicRef68274 graphicRef81632 \" href=\"UTD.htm?6/30/6632\">",
"     picture 2A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The following characteristics have been proposed as features that identify BCCs with a low likelihood for recurrence after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Location and size",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Less than 6 mm in diameter in high-risk areas (eg, central face, nose, lips, eyelids, eyebrows, periorbital skin, chin, mandible, ears, preauricular and postauricular areas, temples, hands, feet)",
"     </li>",
"     <li>",
"      Less than 10 mm in diameter in other areas of the head and neck",
"     </li>",
"     <li>",
"      Less than 20 mm in diameter in all other areas (excluding hands and feet)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pathology",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Nodular or superficial histopathologic growth pattern (",
"      <a class=\"graphic graphic_picture graphicRef65704 graphicRef57990 \" href=\"UTD.htm?35/42/36520\">",
"       picture 1A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lacks perineural invasion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Other",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Primary lesion (not recurrent)",
"     </li>",
"     <li>",
"      Well-defined clinical borders",
"     </li>",
"     <li>",
"      Lacks history of radiation therapy at site",
"     </li>",
"     <li>",
"      Immunocompetent patient",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    BCCs at low risk for recurrence are most commonly managed with electrodesiccation and curettage (ED&amp;C) or surgical excision. Less frequently used treatments include topical 5-fluorouracil (5-FU) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    , cryosurgery, intralesional injection, and photodynamic therapy. Mohs surgery, a time-intensive and costly procedure that offers complete tumor removal through examination of 100 percent of excised tissue margins, generally is not indicated for the treatment of such lesions. In addition, due to long-term side effects, multiple clinic visits, and expense, radiation therapy is usually reserved for large or aggressive lesions and older patients who cannot tolerate other therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17400?source=see_link\">",
"     \"Mohs surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=see_link&amp;anchor=H12329803#H12329803\">",
"     \"Treatment of basal cell carcinomas at high risk for recurrence\", section on 'Mohs surgery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=see_link&amp;anchor=H12329838#H12329838\">",
"     \"Treatment of basal cell carcinomas at high risk for recurrence\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1207255\">",
"    <span class=\"h2\">",
"     Patient factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient specific factors also play an important role in treatment selection. Physical or functional limitations that affect the ability of patients to tolerate surgery, manage wound care, apply topical therapies, or return for follow-up impact the choice of treatment. Moreover, the cosmetic effects of treatment options must be considered. For example, patients who prefer to avoid the pigmentary changes and scarring that can result from electrodesiccation and curettage (ED&amp;C) or cryosurgery may be better served by other interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16554471\">",
"    <span class=\"h1\">",
"     SURGICAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical options for BCCs at low risk for recurrence include electrodesiccation and curettage (ED&amp;C), conventional surgical excision, and cryosurgery. Cryosurgery is infrequently used for this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Electrodesiccation and curettage (ED&amp;C)",
"    </span>",
"    &nbsp;&mdash;&nbsp;ED&amp;C has an important role in the treatment of BCCs. It is primarily used for lesions on the trunk and extremities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link&amp;anchor=H23#H23\">",
"     \"Dermatologic procedures\", section on 'Curettage and electrodesiccation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;With proper lesion selection and operator skill, ED&amp;C is capable of excellent cure rates [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. A review of more than 2000 BCCs treated with ED&amp;C between 1955 and 1982 found that the overall five-year recurrence rate was 13 percent for primary BCCs, and 18 percent for recurrent BCCs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of the anatomic location and size of the lesion is illustrated by a subgroup analysis of the 521 primary BCCs treated with ED&amp;C between 1973 and 1982 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BCCs in low-risk sites (neck, trunk, and extremities) had a 3 percent recurrence rate.",
"     </li>",
"     <li>",
"      Lesions less than 10 mm in diameter and located on the scalp, forehead, preauricular and postauricular areas, or the malar areas had a 5 percent rate of recurrence. Lesions in these sites greater than 10 mm had a recurrence rate of 23 percent.",
"     </li>",
"     <li>",
"      BCCs less than 6 mm in diameter in high-risk sites (nose, paranasal, nasolabial groove, ear, chin, mandibular, perioral, periocular areas) had a 5 percent failure rate, while tumors greater than 6 mm had a recurrence rate of 18 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In other series, reported recurrence rates for BCCs with features associated with increased risk for recurrence are as high as 43 percent, depending upon the tumor location [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Five-year recurrence rates are considerably higher for recurrent BCCs than for primary lesions, particularly those in high-risk sites [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/2,7\">",
"     2,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;BCCs located in the mid-face (including the mid-nose, nasal alae and sulci, medial canthi, and nasolabial folds) should not be treated by ED&amp;C unless they are small (&lt;6 mm), well demarcated, and the cosmetic result is of no consequence to the patient. These areas are formed through the union of several embryologic fusion planes, and offer little resistance to tumor invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/8\">",
"     8",
"    </a>",
"    ]. As a result, tumor buds may extend beyond the reach of the curette. Following inadequate treatment, the skin heals by secondary intent, burying the residual tumor inconspicuously beneath the scar. There, the tumor can grow extensively before it becomes clinically obvious. BCCs located in these areas are best treated by conventional excision or Mohs surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=see_link\">",
"     \"Treatment of basal cell carcinomas at high risk for recurrence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Advantages and disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major advantages of ED&amp;C are its ease, rapidity, lesser cost, and better patient tolerance compared to other treatment modalities. The major disadvantages are the considerable experience required to achieve consistently low recurrence rates, its limitation primarily to truncal and extremity tumors, and the resulting hypopigmented scar.",
"   </p>",
"   <p>",
"    ED&amp;C is generally well tolerated. An unpleasant smell of smoke is produced during the procedure. Minor, harmless electrical shocks may occur in improperly grounded patients who inadvertently touch metal on the treatment table.",
"   </p>",
"   <p>",
"    Rare, serious complications can include burns, fires usually caused by the careless use of alcohol during the procedure, interference with cardiac pacemakers, and life-threatening electrical shocks. There is the potential for explosions in the presence of flammable anesthetic agents, oxygen, or colonic gas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3588991\">",
"    <span class=\"h3\">",
"     Curettage alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of a few retrospective studies suggest that curettage alone may be effective for the treatment of BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. However, additional studies are necessary to clarify the risks and benefits of this treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16554092\">",
"    <span class=\"h2\">",
"     Surgical excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical excision is used for the treatment of both BCCs at low and high risk for recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=see_link&amp;anchor=H1031894#H1031894\">",
"     \"Treatment of basal cell carcinomas at high risk for recurrence\", section on 'Surgical excision'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1207457\">",
"    <span class=\"h3\">",
"     Results and indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the efficacy of surgical excision for BCC are primarily limited to retrospective case series and a few randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. Because surgical excision of truncal, extremity, or small facial BCCs on the head or neck with 4 to 5 mm margins has been associated with five-year cure rates exceeding 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/12-14,17\">",
"     12-14,17",
"    </a>",
"    ], 4 mm surgical margins are commonly used for the excision of these lesions.",
"   </p>",
"   <p>",
"    However, the results of a 2010 meta-analysis of published studies on conventionally excised BCCs that excluded studies of previously excised or irradiated lesions and data on morpheaform BCCs (all features associated with increased risk tumor for recurrence) suggest that 3 mm surgical margins may be only slightly less efficacious [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/18\">",
"     18",
"    </a>",
"    ]. Rates of pathologically confirmed complete excisions were similar for surgical margins between 3 and 5 mm, and recurrence rates for BCCs excised with 5 mm, 4 mm, 3 mm, and 2 mm surgical margins were 0.39 &plusmn; 0.26, 1.62 &plusmn; 1.8, 2.56 &plusmn; 1.6, and 3.96 &plusmn; 1.9 percent, respectively.",
"   </p>",
"   <p>",
"    The efficacy of conventional excision is less consistent in the management of BCCs at greater risk for recurrence. Examples of reported cure rates that support this conclusion include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary BCCs &gt;15, &gt;20, or &gt;30 mm in diameter; 88, 83, and 77 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/13,19\">",
"       13,19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Tumors located on higher risk areas of the face and head (ie, lips, nose, paranasal or periocular region, ears, scalp); 57 to 82 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/12-14,19\">",
"       12-14,19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Recurrent tumors; 83 to 92 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1207464\">",
"    <span class=\"h3\">",
"     Advantages and disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical excision can be performed faster than Mohs surgery, is relatively inexpensive if frozen sections are not performed, and provides some information on surgical margins. Excision is typically performed in an outpatient setting under local anesthesia and is usually well tolerated. The long-term cosmetic and functional results are usually superior compared to radiation therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=see_link&amp;anchor=H12329838#H12329838\">",
"     \"Treatment of basal cell carcinomas at high risk for recurrence\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The surgical defect typically is immediately repaired either by side-side closure, or the use of adjacent tissue flaps, skin grafts, or, more rarely, distant tissue flaps. This allows wound healing to be completed within one to two weeks. If primary closure is not possible, healing can take place by secondary intention. The type of closure depends upon several factors including the size, depth, and location of the defect, the availability and laxity of nearby tissue, and patient and physician preference.",
"   </p>",
"   <p>",
"    Disadvantages of surgical excision include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical excision is invasive and variable amounts of normal, uninvolved tissue must be sacrificed to achieve acceptable cure rates. In some anatomic areas, functional",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cosmetic deficits may be produced.",
"     </li>",
"     <li>",
"      Skin grafts or flaps are frequently needed for larger lesions, and operative time is longer than that required for other procedures (such as cryosurgery and electrosurgery), particularly if a complicated reconstruction is necessary.",
"     </li>",
"     <li>",
"      Surgical excision is more expensive than cryosurgery or ED&amp;C.",
"     </li>",
"     <li>",
"      For lesions at higher risk for recurrence, surgical excision offers inferior cure rates compared to Mohs micrographic excision.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20395822\">",
"    <span class=\"h3\">",
"     Management of incompletely excised lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 0.7 to 50 percent of patients who undergo conventional surgical excision for the removal of BCC, postoperative examination of the tissue specimen reveals tumor extending into the margins of the excised specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spontaneous regression of BCC may occur after incomplete excision; the identification of residual tumor in reexcision tissue specimens has been reported in 14 to 69 percent of specimens, and rates of clinical recurrence after incomplete excision range from 0 to 44 percent (mean 27 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/18,22\">",
"     18,22",
"    </a>",
"    ]. Thus, management of these incompletely excised lesions is controversial. One review of published studies between 1998 and 2008 found that incompletely excised lesions were reexcised in 34 to 76 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who do not undergo immediate treatment for positive margins, lesion recurrence may be delayed. While the majority of recurrences of scalp, superficial, or keratotic BCCs appear to occur within two years, BCCs may recur after longer periods [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to the relatively high risk for lesion recurrence, we thoroughly discuss the risks and benefits of treatment with all patients with incompletely excised BCCs. Factors such as patient preference, tumor morphology and location, presence or absence of aggressive clinical and pathologic features, and patient tolerance for an additional procedure influence the decision of whether to proceed with additional therapy and affect the choice of treatment.",
"   </p>",
"   <p>",
"    For most patients, we manage incompletely excised lesions with conventional surgical excision or Mohs surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/1\">",
"     1",
"    </a>",
"    ]. Less frequently, we utilize radiation therapy. We favor Mohs surgery for the management of incompletely excised BCCs with features associated with a high risk for recurrence and lesions on the head or neck due to the advantage of intraoperative margin control and tissue-sparing. Conventional surgical reexcision is an appropriate option for incompletely excised low-risk lesions on the trunk or extremities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17400?source=see_link\">",
"     \"Mohs surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with incompletely excised lesions that are not surgically amenable or who are not candidates for additional surgery can be treated with radiation. Lesions that cannot be completely removed with Mohs micrographic surgery can also be treated with postoperative radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=see_link&amp;anchor=H12329838#H12329838\">",
"     \"Treatment of basal cell carcinomas at high risk for recurrence\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Close clinical follow-up is warranted for patients who choose to defer treatment for incompletely excised lesions. We see patients at least every three to six months for the first two years after treatment, and then at least once or twice per year. More frequent follow-up may be appropriate, depending on the clinical scenario.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20395993\">",
"    <span class=\"h2\">",
"     Mohs surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mohs micrographic surgery (Mohs surgery) is a specialized surgical technique that optimizes control of the tumor margins while minimizing the amount of normal tissue that must be resected [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/24\">",
"     24",
"    </a>",
"    ]. This procedure allows for histological evaluation of 100 percent of the peripheral margin at the time of the surgical procedure. Mohs surgery is usually reserved for lesions that exhibit features associated with an elevated risk for recurrence and for situations in which tissue sparing is of great value due to cosmetic or functional concerns. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=see_link&amp;anchor=H12329758#H12329758\">",
"     \"Treatment of basal cell carcinomas at high risk for recurrence\", section on 'Features associated with high risk for recurrence'",
"    </a>",
"    .) The procedure is",
"    <strong>",
"     not",
"    </strong>",
"    indicated for small primary BCCs on the trunk or extremities that lack aggressive clinical or histopathologic features because other procedures have similar efficacy and are less time-consuming and less costly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17400?source=see_link\">",
"     \"Mohs surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=see_link&amp;anchor=H12329803#H12329803\">",
"     \"Treatment of basal cell carcinomas at high risk for recurrence\", section on 'Mohs surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H533090\">",
"    <span class=\"h2\">",
"     Cryosurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryosurgery is infrequently used for the treatment of BCC. This technique uses liquid nitrogen to freeze the tumor. Cytotoxicity results from the formation of extracellular and intracellular ice crystals, hypertonic damage, disruption of the cellular phospholipid membrane, and vascular damage through vascular stasis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cryosurgery is cost-effective and requires minimal anesthesia, but there are several disadvantages (",
"    <a class=\"graphic graphic_table graphicRef62863 \" href=\"UTD.htm?9/8/9356\">",
"     table 2",
"    </a>",
"    ). The procedure is contraindicated for patients with lesions with features associated with a high risk for recurrence, those who are concerned about a poor cosmetic outcome, and those with a physiologic intolerance to cold (",
"    <a class=\"graphic graphic_table graphicRef74682 \" href=\"UTD.htm?28/0/28683\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=see_link&amp;anchor=H12329758#H12329758\">",
"     \"Treatment of basal cell carcinomas at high risk for recurrence\", section on 'Features associated with high risk for recurrence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reported cure rates using cryosurgery vary widely for primary BCCs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/26-33\">",
"     26-33",
"    </a>",
"    ]. Although some series report better results, the five-year recurrence rates for primary and recurrent BCCs are approximately 8 and 13 percent, respectively. Treatment can result in permanent hypopigmentation or scarring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16554526\">",
"    <span class=\"h1\">",
"     TOPICAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options for topical therapy include 5-fluorouracil (5-FU) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    . These agents must be applied for several weeks; inflammatory reactions at the sites of application are expected with both medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Topical 5-FU",
"    </span>",
"    &nbsp;&mdash;&nbsp;5-Fluorouracil (5-FU) interferes with DNA synthesis by inhibiting thymidylate synthetase; rapidly proliferating cells are most sensitive to its cytotoxic effect. Topical 5-FU is available in a variety of strengths and formulations; the 5% cream or solution is used for the treatment of BCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extensive experience with topical 5-FU indicates that this treatment modality should be restricted to superficial BCCs in noncritical locations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Some series have observed cure rates of up to 95 percent using 5-FU cream in patients with carefully selected superficial BCCs, although lower cure rates are reported by others [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/34,36-40\">",
"     34,36-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of non-superficial, recurrent, and other high-risk BCCs with 5-FU results in low cure rates [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/36-39,41-43\">",
"     36-39,41-43",
"    </a>",
"    ]. Furthermore, topical treatment in these settings can give the false impression of a cure despite persistent dermal disease. For this reason, nodular and aggressive BCCs are generally considered contraindications to topical 5-FU.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Usage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical 5-FU should be applied as a 5% formulation twice daily for at least three to six weeks. Treatment may require 10 or more weeks depending upon the clinical response. An adequate therapeutic response to topical 5-FU depends upon the 5-FU concentration and vehicle, the frequency of application, the use of an occlusive dressing, clinical and histologic tumor features, the patient's complexion, and the degree of sun exposure before and during treatment.",
"   </p>",
"   <p>",
"    Topical 5-FU causes a brisk inflammatory reaction in the treated sites, which is an indication of activity. Prior to treatment, patients should be thoroughly educated on anticipated side effects, including stinging, burning, pain, erythema, edema, erosions and ulceration with serous oozing, and possible secondary infections. At times, the discomfort can be significant enough to prompt a temporary or permanent discontinuation of therapy, and it is not uncommon for patients to become virtual social recluses during treatment because of the undesirable cosmetic effects.",
"   </p>",
"   <p>",
"    If the inflammatory response is not tolerated, the reaction can usually be ameliorated by temporary discontinuation of therapy, reduction of drug concentration, application of an emollient such as chilled Vaseline or hydrated petrolatum,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    application of an intermediate-potency topical steroid (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Special care should be taken when applying 5-FU to areas near the eyes, lips, and nose because of increased sensitivity of these areas. In addition, patients should avoid intense sun exposure during treatment.",
"   </p>",
"   <p>",
"    Following discontinuation of topical 5-FU therapy, healing generally takes place over the ensuing two or more weeks. The residual erythema and occasional hyperpigmentation usually fade with time. In general, long-term favorable cosmetic results are one of the major advantages of topical 5-FU compared to other treatment modalities. However, scarring has been reported in 9 to 16 percent of patients utilizing topical 5-FU for the treatment of superficial BCC or SCC in situ [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the intended inflammatory response, side effects of topical 5-FU can include posttreatment pigmentary changes, rare cases of allergic contact dermatitis to 5-FU or its vehicle, treatment-associated photosensitivity, and the tendency for topical 5-FU to conceal deeper residual tumor nests in improperly selected or incompletely treated cases.",
"   </p>",
"   <p>",
"    Other unusual side effects include temporary reversible onycholysis and onychodystrophy, persistent telangiectasias, hypertrophic scarring in high-risk areas, and bullous pemphigoid. Systemic absorption of 5-FU can cause cardiac ischemia and other life-threatening systemic toxicity in the rare patient with an inherited deficiency in the metabolizing enzyme dihydropyrimidine dehydrogenase (DPD) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42362?source=see_link&amp;anchor=H5#H5\">",
"     \"Enterotoxicity of chemotherapeutic agents\", section on '5-Fluorouracil'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Imiquimod",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    5% cream is a novel immune response modifier that is approved by the US Food and Drug Administration for the treatment of superficial BCCs in low-risk sites. Imiquimod is thought to promote apoptosis in skin cancer cells by circumventing the anti-apoptotic mechanisms that are developed by tumor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/46\">",
"     46",
"    </a>",
"    ],",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by stimulating",
"    <span class=\"nowrap\">",
"     monocytes/macrophages",
"    </span>",
"    and dendritic cells to produce cytokines that stimulate cell-mediated immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experience with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    for treatment of superficial BCC is encouraging [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. A systematic review summarizing the results of three randomized trials reported an overall cure rate of 81 percent in patients treated at least once daily (five or seven days per week) for 6 to 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/35\">",
"     35",
"    </a>",
"    ]. Cure rates fall off dramatically if the drug is given less frequently. Higher cure rates may be possible with twice daily treatment, but localized reactions can be severe and are dose-limiting.",
"   </p>",
"   <p>",
"    The efficacy of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    was shown in two identical multicenter trials in which a total of 724 patients with superficial BCC were randomly assigned to imiquimod 5% cream once daily five or seven times weekly for six weeks, or topical application of vehicle alone [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/51\">",
"     51",
"    </a>",
"    ]. The lesion site was clinically examined 12 weeks posttreatment and then excised for histologic evaluation.",
"   </p>",
"   <p>",
"    When data from both trials were pooled, the histologic clearance rates for the five-day and seven-day treatment groups were 82 and 79 percent, respectively, compared to 3 percent in the vehicle-treated group. The severity of erythema, erosion and",
"    <span class=\"nowrap\">",
"     scabbing/crusting",
"    </span>",
"    was associated with higher clearance rates. Long-term follow-up was not reported.",
"   </p>",
"   <p>",
"    Treatment of nodular BCCs is less successful. Cure rates are 60 to 75 percent following 6 to 12 weeks of once daily dosing, and &le;65 percent with less frequent dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. The application of an occlusive dressing seems to offer minimal improvement in cure rates [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    may be more effective if combined with curettage prior to application [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/55\">",
"     55",
"    </a>",
"    ], but in most patients the advantages of this approach over curettage combined with traditional modalities such as electrodesiccation or cryosurgery are not apparent.",
"   </p>",
"   <p>",
"    In uncontrolled studies, the effects of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    appear durable [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. This was illustrated by a series of 169 subjects with superficial BCC, who were evaluated serially for two years following treatment. The initial response rate was 94 percent, and approximately 82 percent were disease-free at two years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/56\">",
"     56",
"    </a>",
"    ]. A separate follow-up study of 165 patients with superficial BCC found that among patients who achieved initial clinical clearance of disease, 87 percent remained free of clinical recurrence after five years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/58\">",
"     58",
"    </a>",
"    ]. Infiltrative BCCs appear to have a lower long-term treatment success rate. In a small series in which histologic specimens were used to confirm the initial response to imiquimod, only 60 percent of infiltrative BCCs did not recur after five years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/57\">",
"     57",
"    </a>",
"    ]. Persistent hypopigmentation at the treatment site was a frequent complication of imiquimod therapy.",
"   </p>",
"   <p>",
"    Sporadic case reports suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    5% cream may have a role in treating BCCs in patients with basal cell nevus syndrome and xeroderma pigmentosum [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/59-62\">",
"     59-62",
"    </a>",
"    ]. These patients are predisposed to developing numerous skin cancers, including BCCs, and can be quite difficult to manage. In this setting, topical treatment of primary early, small, or superficial BCCs can be a valuable asset. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44121?source=see_link\">",
"     \"Nevoid basal cell carcinoma syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H523750964#H523750964\">",
"     \"The genodermatoses\", section on 'Xeroderma pigmentosum'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Topical treatment can be associated with systemic effects, including fatigue and an influenza-like illness. Exfoliative dermatitis and angioedema have also been reported.",
"   </p>",
"   <p>",
"    Until more experience about long-term recurrence rates is available,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    use should be reserved for the treatment of primary superficial BCCs in low-risk sites where recurrence is unlikely to be accompanied by substantial morbidity, or in patients with BCCs who are poor surgical candidates",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have a limited life expectancy. In these settings, twice daily regimens are preferred but poorly tolerated. Once daily regimens provide acceptably high cure rates with fewer side-effects. Patients should be informed that there is limited knowledge concerning long-term side effects and recurrence rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2552819\">",
"    <span class=\"h1\">",
"     RADIATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy is an option for the treatment of BCCs in patients who are poor candidates for surgical intervention. Radiation therapy for BCC is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=see_link&amp;anchor=H12329838#H12329838\">",
"     \"Treatment of basal cell carcinomas at high risk for recurrence\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15673478\">",
"    <span class=\"h1\">",
"     INTRALESIONAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intralesional therapies (interferons, 5-FU, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ) are used infrequently for the management of BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. A systematic review of open label studies, case series, and the few randomized trials that have investigated the efficacy of intralesional interferon for BCC found overall cure rates for interferon beta, interferon alfa-2a, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29576?source=see_link\">",
"     interferon alfa-2b",
"    </a>",
"    of 63, 68, and 76 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/63\">",
"     63",
"    </a>",
"    ]. Data are limited on the use of intralesional 5-FU and bleomycin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/63\">",
"     63",
"    </a>",
"    ]. However, the results of a few case reports and small case series suggest that these therapies may be highly effective for BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/65-68\">",
"     65-68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects of intralesional interferon, 5-FU, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    include local pain, erythema, necrosis, and ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/63\">",
"     63",
"    </a>",
"    ]. Systemic side effects are less likely with intralesional injection than with systemic administration, but may also occur. Risks of interferon therapy include fever, malaise, headaches, myalgias, cytopenia, hepatotoxicity, and nephrotoxicity. Pulmonary toxicity, cutaneous sclerosis, and Raynaud phenomenon have been associated with bleomycin. Gastrointestinal distress and cytopenias are potential adverse effects of 5-FU.",
"   </p>",
"   <p>",
"    Evidence is limited on the long term efficacy of intralesional therapies. Treatment is generally reserved for patients in whom surgical therapy is not an option, especially in the setting of lesions at high risk for recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PHOTODYNAMIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photodynamic therapy (PDT) uses light and porphyrins to cause tumor destruction. The selectivity of PDT is based upon the application of the agent to the tumor, which results in a higher concentration of the porphyrins within the cancerous cells, and the ability to focus light on the involved area. Although PDT has been approved for the treatment of BCC in many European countries, US FDA approval has not been granted for the treatment of BCC.",
"   </p>",
"   <p>",
"    To perform PDT, a photosensitizing porphyrin (5-aminolevulinic acid [ALA],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/7/35955?source=see_link\">",
"     methyl aminolevulinate",
"    </a>",
"    [MAL]) is applied topically to the lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/69\">",
"     69",
"    </a>",
"    ]. Although a porphyrin (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39157?source=see_link\">",
"     porfimer",
"    </a>",
"    ) can be administered systemically, this approach is used rarely since systemic therapy can be associated with prolonged photosensitivity.",
"   </p>",
"   <p>",
"    Several hours after topical application of the porphyrin, the area is exposed to visible light emitted from a designated light source (usually a blue light [400 to 450 nm] or red light [630 to 635 nm range]). The light penetrates the skin and is selectively absorbed by the photosensitizer, which generates reactive oxygen species. This in turn can cause lipid peroxidation, protein crosslinking, increased membrane permeability, and ultimately cell death. In addition to direct effects on tumor cells, PDT can damage blood vessels, resulting in impaired blood flow, and can stimulate a vigorous local inflammatory reaction that may contribute to tumor destruction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors such as the characteristics of the BCC treated and the protocol used for PDT may contribute to the observed variability in response rates. Superficial lesions appear to be most responsive to therapy; cure rates have ranged from 82 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. A randomized trial (n = 196) comparing the efficacy of MAL-PDT to surgical excision for the treatment of small (8 to 20 mm) superficial BCCs found lesion recurrence rates after 12 months of 9 percent in patients treated with PDT versus 0 percent in patients treated with conventional excision [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/15\">",
"     15",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Nodular BCCs are less likely than superficial BCCs to respond to treatment with PDT [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Reported cure rates in the literature have ranged from 10 to 76 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/71\">",
"     71",
"    </a>",
"    ]. PDT was compared to surgical excision in a multicenter trial in which 109 patients with nodular BCC were randomly assigned to PDT with MAL or surgical excision [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/75\">",
"     75",
"    </a>",
"    ]. Sixty-six patients completed follow-up for five years. Based upon the available data, the estimated sustained complete response rate was significantly lower with MAL-PDT (76 percent versus 96 percent with surgery). However, a good or excellent cosmetic outcome was significantly more frequent in patients treated with PDT (87 versus 54 percent).",
"   </p>",
"   <p>",
"    Approaches to enhance the efficacy of PDT have included administering multiple treatment sessions; combining ALA with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33123?source=see_link\">",
"     dimethylsulfoxide",
"    </a>",
"    (DMSO, a drug penetration enhancer), hyperthermia, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    ; extending the ALA application time; applying the photosensitizer with an occlusive dressing; combining ALA with curettage of the lesion or carbon dioxide laser; and administering ALA by intralesional rather than topical application [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/76-84\">",
"     76-84",
"    </a>",
"    ]. None of these approaches has an established role in the treatment of BCCs.",
"   </p>",
"   <p>",
"    Side effects from topical PDT include prolonged photosensitivity (up to two to three days in our experience), pain, burning, erythema, edema, ulceration, and temporary pigmentary change at the treated site. Healing is usually complete within two weeks and scarring is unusual.",
"   </p>",
"   <p>",
"    One of the longest follow-up studies of PDT for BCC is a 10-year study of 44 patients with 55 primary BCCs and 5 recurrent BCCs (including 14 superficial BCCs, 28 nodular BCCs, and 17 BCCs with micronodular, morpheaform, or infiltrative histology) that were treated with one or two sessions of ALA-PDT after pretreatment with DMSO and curettage [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/85\">",
"     85",
"    </a>",
"    ]. Ten patients with BCCs died during the follow-up period. Of the initial 55 primary BCCs treated, 12 (22 percent) failed treatment. All documented episodes of tumor recurrence occurred within the first three years. Of note, patients who received two ALA-PDT sessions had better outcomes than patients who received only one treatment session. Cosmetic outcomes were good or excellent in the sites of all 33 successfully treated BCCs that were available for evaluation after 10 years. Additional studies are required to confirm the long-term recurrence rate for BCC following topical PDT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for most patients with BCC is excellent. These lesions are typically slow-growing, and metastatic disease is a very rare event.",
"   </p>",
"   <p>",
"    Although the mortality rate is very low in BCC, these cancers may result in significant morbidity. BCCs can cause considerable disfigurement by locally destroying skin, cartilage and even bone (",
"    <a class=\"graphic graphic_picture graphicRef68274 graphicRef81632 \" href=\"UTD.htm?6/30/6632\">",
"     picture 2A-B",
"    </a>",
"    ). Untreated advanced lesions typically ulcerate, creating wound care problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13999098\">",
"    <span class=\"h2\">",
"     Metastasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the metastatic rate of BCC have ranged from 0.0029 to 0.55 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/86\">",
"     86",
"    </a>",
"    ]. In one report documenting the rate of metastasis among approximately 6000 patients with BCC, the rate of metastasis for BCC estimated to be 0.1 percent, while other studies have found an even lower incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/86\">",
"     86",
"    </a>",
"    ]. In another report, the population-based case mortality rate from BCC was approximately 0.05 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/87\">",
"     87",
"    </a>",
"    ]. Men develop metastatic disease more frequently than women, although the reason for this is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15063?source=see_link&amp;anchor=H19784616#H19784616\">",
"     \"Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma\", section on 'Basal cell carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Metastatic lesions usually occur in association with deeply invasive or large lesions, with an area of greater than 10 cm",
"    <sup>",
"     2",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/86\">",
"     86",
"    </a>",
"    ]. Common sites for metastasis include the regional lymph nodes, lungs, bones, skin, and liver [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/88\">",
"     88",
"    </a>",
"    ]. The prognosis for metastatic BCC is poor; mean survival rates range from 8 months to 3.6 years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. Systemic therapy for locally advanced or metastatic BCC is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14293?source=see_link\">",
"     \"Systemic treatment of advanced cutaneous squamous and basal cell carcinomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     New primary skin cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 percent of patients with one BCC subsequently develop another primary BCC within one year, and roughly 40 percent develop a new BCC within five years after their original diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/91-95\">",
"     91-95",
"    </a>",
"    ]. This risk increases further for patients with more than one previous BCC and is especially high in fair-skinned individuals. Younger patients may also be at increased risk for multiple lesions. In a Dutch cohort study of people age 55 and older (n = 10,820), the risk of developing an additional BCC was significantly lower among those who developed the first lesion after age 75 (adjusted OR 0.58; 95% CI 0.47-0.71) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/96\">",
"     96",
"    </a>",
"    ]. Other factors that increased the risk for additional BCCs included red hair (adjusted OR 1.43, 95% CI 1.05-1.94), high educational level (adjusted OR 1.42, 95% CI 1.12-1.81), and the upper extremities as the location of the first BCC (adjusted OR 1.49, 95% CI 1.02-2.15).",
"   </p>",
"   <p>",
"    Although the greatest risk for a subsequent BCC is within the first two years, at least one study suggests that annual risk remains high throughout five years and is 10 to 12 times the rate expected in the general population (ie, 10 to 12 percent versus 1 percent per year) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/93\">",
"     93",
"    </a>",
"    ]. Roughly one-fourth of these patients will detect the new BCCs themselves, underscoring the importance of periodic full skin examinations by a medical practitioner [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/92\">",
"     92",
"    </a>",
"    ]. Earlier detection may discover tumors that are smaller, less aggressive, and at a lower risk of recurrence.",
"   </p>",
"   <p>",
"    Patients who develop a BCC are also at increased risk of developing both SCCs and melanomas. The risk of subsequently developing a SCC is believed to be between 5 and 10 percent while the risk of developing melanoma is two to fourfold greater than the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Other second cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both BCC and cutaneous squamous cell carcinoma have been associated with a modest increase in the incidence of subsequent malignancy. The relationship of nonmelanoma skin cancers to second malignancies is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment and prognosis of cutaneous squamous cell carcinoma\", section on 'Other second cancers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Close follow-up is required following treatment to detect both local recurrences and new skin cancers and to assess posttreatment effects. Most dermatologists recommend reevaluation every six months for the first year following treatment, and then annually. In the absence of recurrent tumor or new actinic keratoses, further follow-up can be on an \"as needed\" basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Local recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 50 percent of recurrences are apparent within the first two years, two-thirds within three years, 80 percent within five years, and roughly 20 percent between 5 and 10 years following treatment of an initial BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?13/23/13690/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Periodic evaluation for local recurrence should include not only visual inspection but also palpation of the skin and adjacent structures to determine the presence of deeper recurrences. Patients should be asked about any visible, textural, or sensory changes of the treated area, and any suspicious or questionable areas confirmed histologically with a biopsy. For suspected deeper recurrences, one or more punch biopsies should be obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H608006\">",
"    <span class=\"h2\">",
"     Cosmetic and functional outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending on the type and extent of treatment, patients may be left with cosmetic or functional defects after treatment. Care should be taken to address patient concerns through reassurance or appropriate therapeutic interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Education regarding preventive measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important component of follow-up in a patient with a skin cancer is education concerning modification of risk factors. Although the impact of sun avoidance in decreasing the risk of further BCCs is unclear, it seems prudent to advocate moderate sun avoidance in patients with a history of skin cancer, especially in fairer-skinned patients. These recommendations generally include sun avoidance during peak hours (10 AM and 4 PM), use of a broad spectrum sunscreen (both UVA and UVB), wearing sun protective clothing, sunglasses and a broad-brimmed hat, avoiding sun bathing and tanning salons, and practicing routine self-skin examinations monthly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18073?source=see_link\">",
"     \"Primary prevention of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/26/26018?source=see_link\">",
"       \"Patient information: Skin cancer (non-melanoma) (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H532754\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BCCs present with a variety of clinical and pathological features. The selection of appropriate therapy is dependent upon lesion characteristics and patient-specific factors. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electrodesiccation and curettage (ED&amp;C) is commonly used for the management of BCCs on the trunk and extremities that lack clinical or pathological features associated with a high risk for recurrence. Treatment is quick and generally well-tolerated. The hypopigmented scar that develops after ED&amp;C limits its use on cosmetically sensitive areas. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Electrodesiccation and curettage (ED&amp;C)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical excision is another common, highly efficacious treatment available for the management of BCC. Excised tissue should be sent for pathological assessment for tumor margins. (See",
"      <a class=\"local\" href=\"#H16554092\">",
"       'Surgical excision'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For superficial low-risk BCCs, we suggest treatment with excision, electrodesiccation and curettage (ED&amp;C), or topical 5-fluorouracil or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We typically manage nodular BCCs with ED&amp;C or surgical excision. (See",
"      <a class=\"local\" href=\"#H16554471\">",
"       'Surgical therapies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16554526\">",
"       'Topical therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Photodynamic therapy is a newer modality that has been used for the treatment of BCC. Photodynamic therapy appears to be most efficacious for the treatment of superficial lesions. Additional studies are necessary to determine the long-term safety and optimal treatment regimens for this modality. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Photodynamic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Careful follow-up is important to evaluate for evidence of local recurrence, additional primary skin tumors (including BCC, squamous cell carcinoma, and melanoma), and for late complications of treatment. We typically reevaluate every six months for the first year following treatment, and then yearly. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/1\">",
"      Miller SJ, Alam M, Andersen J, et al. Basal cell and squamous cell skin cancers. J Natl Compr Canc Netw 2010; 8:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/2\">",
"      Silverman MK, Kopf AW, Grin CM, et al. Recurrence rates of treated basal cell carcinomas. Part 2: Curettage-electrodesiccation. J Dermatol Surg Oncol 1991; 17:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/3\">",
"      Chren MM, Linos E, Torres JS, et al. Tumor Recurrence 5 Years after Treatment of Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma. J Invest Dermatol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/4\">",
"      Salasche SJ. Curettage and electrodesiccation in the treatment of midfacial basal cell epithelioma. J Am Acad Dermatol 1983; 8:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/5\">",
"      Suhge d'Aubermont PC, Bennett RG. Failure of curettage and electrodesiccation for removal of basal cell carcinoma. Arch Dermatol 1984; 120:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/6\">",
"      Blixt E, Nelsen D, Stratman E. Recurrence Rates of Aggressive Histologic Types of Basal Cell Carcinoma After Treatment with Electrodesiccation and Curettage Alone. Dermatol Surg 2013.",
"     </a>",
"    </li>",
"    <li>",
"     Sebben JE. Cutaneous Electrosurgery, Year Book Medical Publishers, Inc., New York 1989. p.p.139.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/8\">",
"      Panje WR, Ceilley RI. The influence of embryology of the mid-face on the spread of epithelial malignancies. Laryngoscope 1979; 89:1914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/9\">",
"      Barlow JO, Zalla MJ, Kyle A, et al. Treatment of basal cell carcinoma with curettage alone. J Am Acad Dermatol 2006; 54:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/10\">",
"      McDaniel WE. Therapy for basal cell epitheliomas by curettage only. Further study. Arch Dermatol 1983; 119:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/11\">",
"      Reymann F. 15 years' experience with treatment of basal cell carcinomas of the skin with curettage. Acta Derm Venereol Suppl (Stockh) 1985; 120:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/12\">",
"      Dubin N, Kopf AW. Multivariate risk score for recurrence of cutaneous basal cell carcinomas. Arch Dermatol 1983; 119:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/13\">",
"      Silverman MK, Kopf AW, Bart RS, et al. Recurrence rates of treated basal cell carcinomas. Part 3: Surgical excision. J Dermatol Surg Oncol 1992; 18:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/14\">",
"      Bart RS, Schrager D, Kopf AW, et al. Scalpel excision of basal cell carcinomas. Arch Dermatol 1978; 114:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/15\">",
"      Szeimies RM, Ibbotson S, Murrell DF, et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol 2008; 22:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/16\">",
"      Berroeta L, Clark C, Dawe RS, et al. A randomized study of minimal curettage followed by topical photodynamic therapy compared with surgical excision for low-risk nodular basal cell carcinoma. Br J Dermatol 2007; 157:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/17\">",
"      Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. Arch Dermatol 1987; 123:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/18\">",
"      Gulleth Y, Goldberg N, Silverman RP, Gastman BR. What is the best surgical margin for a Basal cell carcinoma: a meta-analysis of the literature. Plast Reconstr Surg 2010; 126:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/19\">",
"      Rowe DE, Carroll RJ, Day CL Jr. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol 1989; 15:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/20\">",
"      Smeets NW, Krekels GA, Ostertag JU, et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet 2004; 364:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/21\">",
"      Malik V, Goh KS, Leong S, et al. Risk and outcome analysis of 1832 consecutively excised basal cell carcinomas in a tertiary referral plastic surgery unit. J Plast Reconstr Aesthet Surg 2010; 63:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/22\">",
"      Palmer VM, Wilson PR. Incompletely Excised Basal Cell Carcinoma: Residual Tumor Rates at Mohs Re-Excision. Dermatol Surg 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/23\">",
"      Robinson JK, Fisher SG. Recurrent basal cell carcinoma after incomplete resection. Arch Dermatol 2000; 136:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/24\">",
"      Muller FM, Dawe RS, Moseley H, Fleming CJ. Randomized comparison of Mohs micrographic surgery and surgical excision for small nodular basal cell carcinoma: tissue-sparing outcome. Dermatol Surg 2009; 35:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/25\">",
"      Kuflik EG. Cryosurgery for cutaneous malignancy. An update. Dermatol Surg 1997; 23:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/26\">",
"      Kuflik EG, Gage AA. The five-year cure rate achieved by cryosurgery for skin cancer. J Am Acad Dermatol 1991; 24:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/27\">",
"      Graham GF. Cryosurgery. Clin Plast Surg 1993; 20:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/28\">",
"      Zacarian SA. Cryosurgery of cutaneous carcinomas. An 18-year study of 3,022 patients with 4,228 carcinomas. J Am Acad Dermatol 1983; 9:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/29\">",
"      Holt PJ. Cryotherapy for skin cancer: results over a 5-year period using liquid nitrogen spray cryosurgery. Br J Dermatol 1988; 119:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/30\">",
"      Biro L, Price E, Brand A. Cryosurgery for basal cell carcinoma of the eyelids and nose: five-year experience. J Am Acad Dermatol 1982; 6:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/31\">",
"      Biro L, Price E. Cryosurgical management of basal cell carcinoma of the eyelid: a 10-year experience. J Am Acad Dermatol 1990; 23:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/32\">",
"      Wang I, Bendsoe N, Klinteberg CA, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 2001; 144:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/33\">",
"      Thissen MR, Nieman FH, Ideler AH, et al. Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatol Surg 2000; 26:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/34\">",
"      Goette DK. Topical chemotherapy with 5-fluorouracil. A review. J Am Acad Dermatol 1981; 4:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/35\">",
"      Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol 2009; 145:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/36\">",
"      Reymann F. Treatment of basal cell carcinoma of the skin with 5-fluorouracil ointment. A 10-year follow-up study. Dermatologica 1979; 158:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/37\">",
"      Klein E, Stoll HL Jr, Milgrom H, et al. Tumors of the skin. XII. Topical 5-Fluorouracil for epidermal neoplasms. J Surg Oncol 1971; 3:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/38\">",
"      Johnson A. Topical use of 5-fluorouracil. Med J Aust 1973; 1:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/39\">",
"      Ebner, H. Treatment of skin epitheliomas with 5-fluorouracil (5-FU) ointment. Influence of therapeutic design on recurrence of lesions. Dermatologica 1970; 140:Suppl.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/40\">",
"      Romagosa R, Saap L, Givens M, et al. A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier. Dermatol Surg 2000; 26:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/41\">",
"      Klostermann, GF. Basal-cell carcinoma of large dimension. Dermatologica 1970; 140:Suppl.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/42\">",
"      Mohs FE, Jones DL, Bloom RF. Tendency of fluorouracil to conceal deep foci of invasive basal cell carcinoma. Arch Dermatol 1978; 114:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/43\">",
"      Epstein E. Fluorouracil paste treatment of thin basal cell carcinomas. Arch Dermatol 1985; 121:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/44\">",
"      Rozenman Y, Gurewich J, Gotsman MS. Myocardial ischemia induced by topical use of 5-fluorouracil. Int J Cardiol 1995; 49:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/45\">",
"      Johnson MR, Hageboutros A, Wang K, et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 1999; 5:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/46\">",
"      Sch&ouml;n M, Bong AB, Drewniok C, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/47\">",
"      Miller R. Imiquimod stimulates innate and cell mediated immunity which controls virus infections and tumors. Int J Dermatol 2002; 41 Suppl 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/48\">",
"      Urosevic M, Dummer R, Conrad C, et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 2005; 97:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/49\">",
"      Daud&eacute;n E, BASALE Study Group. Effectiveness and satisfaction with imiquimod for the treatment of superficial basal cell carcinoma in daily dermatological practice. J Eur Acad Dermatol Venereol 2011; 25:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/50\">",
"      Garcia-Martin E, Gil-Arribas LM, Idoipe M, et al. Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. Br J Ophthalmol 2011; 95:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/51\">",
"      Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/52\">",
"      Eigentler TK, Kamin A, Weide BM, et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol 2007; 57:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/53\">",
"      Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 2002; 138:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/54\">",
"      Sterry W, Ruzicka T, Herrera E, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002; 147:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/55\">",
"      Neville JA, Williford PM, Jorizzo JL. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage. J Drugs Dermatol 2007; 6:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/56\">",
"      Quirk C, Gebauer K, Owens M, Stampone P. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks. Australas J Dermatol 2006; 47:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/57\">",
"      Vidal D, Mat&iacute;as-Guiu X, Alomar A. Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up. Arch Dermatol 2007; 143:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/58\">",
"      Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol 2008; 18:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/59\">",
"      Kagy MK, Amonette R. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient. Dermatol Surg 2000; 26:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/60\">",
"      Stockfleth E, Ulrich C, Hauschild A, et al. Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod. Eur J Dermatol 2002; 12:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/61\">",
"      Weisberg NK, Varghese M. Therapeutic response of a brother and sister with xeroderma pigmentosum to imiquimod 5% cream. Dermatol Surg 2002; 28:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/62\">",
"      Ferreres JR, Macaya A, Jucgl&agrave; A, et al. Hundreds of basal cell carcinomas in a Gorlin-Goltz syndrome patient cured with imiquimod 5% cream. J Eur Acad Dermatol Venereol 2006; 20:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/63\">",
"      Kirby JS, Miller CJ. Intralesional chemotherapy for nonmelanoma skin cancer: a practical review. J Am Acad Dermatol 2010; 63:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/64\">",
"      Good LM, Miller MD, High WA. Intralesional agents in the management of cutaneous malignancy: a review. J Am Acad Dermatol 2011; 64:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/65\">",
"      Avant WH, Huff RC. Intradermal 5-fluorouracil in the treatment of basal cell carcinoma of the face. South Med J 1976; 69:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/66\">",
"      Kurtis B, Rosen T. Treatment of cutaneous neoplasms by intralesional injections of 5-fluorouracil (5-FU). J Dermatol Surg Oncol 1980; 6:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/67\">",
"      Gyurova MS, Stancheva MZ, Arnaudova MN, Yankova RK. Intralesional bleomycin as alternative therapy in the treatment of multiple basal cell carcinomas. Dermatol Online J 2006; 12:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/68\">",
"      Mishima Y, Matunaka M. Effect of bleomycin on benign and malignant cutaneous tumours. Acta Derm Venereol 1972; 52:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/69\">",
"      Foley P. Clinical efficacy of methyl aminolevulinate (Metvix) photodynamic therapy. J Dermatolog Treat 2003; 14 Suppl 3:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/70\">",
"      Kalka K, Merk H, Mukhtar H. Photodynamic therapy in dermatology. J Am Acad Dermatol 2000; 42:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/71\">",
"      Fantini F, Greco A, Del Giovane C, et al. Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response. J Eur Acad Dermatol Venereol 2011; 25:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/72\">",
"      Cosgarea R, Susan M, Crisan M, Senila S. Photodynamic therapy using topical 5-aminolaevulinic acid vs. surgery for basal cell carcinoma. J Eur Acad Dermatol Venereol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/73\">",
"      Li Q, Gao T, Jiao B, et al. Tumor thickness predicts long-term complete response of facial basal cell carcinomas in Asian skin types iv/v treated with methyl aminolaevulinate photodynamic therapy. Photomed Laser Surg 2011; 29:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/74\">",
"      Mosterd K, Thissen MR, Nelemans P, et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. Br J Dermatol 2008; 159:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/75\">",
"      Rhodes LE, de Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol 2007; 143:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/76\">",
"      Morton CA, MacKie RM, Whitehurst C, et al. Photodynamic therapy for basal cell carcinoma: effect of tumor thickness and duration of photosensitizer application on response. Arch Dermatol 1998; 134:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/77\">",
"      Fijan S, H&ouml;nigsmann H, Ortel B. Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferrioxamine. Br J Dermatol 1995; 133:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/78\">",
"      Soler AM, Angell-Petersen E, Warloe T, et al. Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid: a comparison of two light sources. Photochem Photobiol 2000; 71:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/79\">",
"      Calzavara-Pinton PG. Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. J Photochem Photobiol B 1995; 29:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/80\">",
"      Morton CA, Whitehurst C, McColl JH, et al. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol 2001; 137:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/81\">",
"      Pass HI. Photodynamic therapy in oncology: mechanisms and clinical use. J Natl Cancer Inst 1993; 85:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/82\">",
"      Soler AM, Warloe T, Tausj&oslash; J, Berner A. Photodynamic therapy by topical aminolevulinic acid, dimethylsulphoxide and curettage in nodular basal cell carcinoma: a one-year follow-up study. Acta Derm Venereol 1999; 79:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/83\">",
"      Shokrollahi K, Javed M, Aeuyung K, et al. Combined Carbon Dioxide Laser with Photodynamic Therapy for Nodular and Superficial Basal Cell Carcinoma: Almost Scarless Cure With Minimal Recurrence. Ann Plast Surg 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/84\">",
"      Rodr&iacute;guez-Prieto M&Aacute;, Gonz&aacute;lez-Sixto B, P&eacute;rez-Bustillo A, et al. Photodynamic therapy with intralesional photosensitizer and laser beam application: an alternative treatment for nodular basal cell carcinoma. J Am Acad Dermatol 2012; 67:e134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/85\">",
"      Christensen E, M&oslash;rk C, Skogvoll E. High and sustained efficacy after two sessions of topical 5-aminolaevulinic acid photodynamic therapy for basal cell carcinoma: a prospective, clinical and histological 10-year follow-up study. Br J Dermatol 2012; 166:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/86\">",
"      von Domarus H, Stevens PJ. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol 1984; 10:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/87\">",
"      Weinstock MA, Bogaars HA, Ashley M, et al. Nonmelanoma skin cancer mortality. A population-based study. Arch Dermatol 1991; 127:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/88\">",
"      Ting PT, Kasper R, Arlette JP. Metastatic basal cell carcinoma: report of two cases and literature review. J Cutan Med Surg 2005; 9:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/89\">",
"      Snow SN, Sahl W, Lo JS, et al. Metastatic basal cell carcinoma. Report of five cases. Cancer 1994; 73:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/90\">",
"      Walling HW, Fosko SW, Geraminejad PA, et al. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev 2004; 23:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/91\">",
"      Karagas MR, Stukel TA, Greenberg ER, et al. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. Skin Cancer Prevention Study Group. JAMA 1992; 267:3305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/92\">",
"      Robinson JK. Risk of developing another basal cell carcinoma. A 5-year prospective study. Cancer 1987; 60:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/93\">",
"      Marghoob A, Kopf AW, Bart RS, et al. Risk of another basal cell carcinoma developing after treatment of a basal cell carcinoma. J Am Acad Dermatol 1993; 28:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/94\">",
"      Schreiber MM, Moon TE, Fox SH, Davidson J. The risk of developing subsequent nonmelanoma skin cancers. J Am Acad Dermatol 1990; 23:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/95\">",
"      Schinstine M, Goldman GD. Risk of synchronous and metachronous second nonmelanoma skin cancer when referred for Mohs micrographic surgery. J Am Acad Dermatol 2001; 44:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/96\">",
"      Kiiski V, de Vries E, Flohil SC, et al. Risk factors for single and multiple basal cell carcinomas. Arch Dermatol 2010; 146:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/23/13690/abstract/97\">",
"      Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989; 15:315.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5338 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-CA557B663F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_23_13690=[""].join("\n");
var outline_f13_23_13690=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H532754\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20396140\">",
"      Tumor characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1207255\">",
"      Patient factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16554471\">",
"      SURGICAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Electrodesiccation and curettage (ED&amp;C)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Advantages and disadvantages",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3588991\">",
"      - Curettage alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16554092\">",
"      Surgical excision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1207457\">",
"      - Results and indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1207464\">",
"      - Advantages and disadvantages",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20395822\">",
"      - Management of incompletely excised lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20395993\">",
"      Mohs surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H533090\">",
"      Cryosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16554526\">",
"      TOPICAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Topical 5-FU",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Usage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Imiquimod",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2552819\">",
"      RADIATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15673478\">",
"      INTRALESIONAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PHOTODYNAMIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13999098\">",
"      Metastasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      New primary skin cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Other second cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Local recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H608006\">",
"      Cosmetic and functional outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Education regarding preventive measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H532754\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5338\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5338|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/50/17188\" title=\"picture 1A\">",
"      Superficial basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/56/17283\" title=\"picture 1B\">",
"      Nodular basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/13/43217\" title=\"picture 2A\">",
"      Large basal cell carcinoma on nose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/28/44483\" title=\"picture 2B\">",
"      Large basal cell carcinoma on ear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5338|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/27/31164\" title=\"table 1A\">",
"      Treatment summary I BCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/37/31324\" title=\"table 1B\">",
"      Treatment summary II BCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/8/9356\" title=\"table 2\">",
"      Cryosurg BCC advant disadvant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/0/28683\" title=\"table 3\">",
"      Cryosurg BCC contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 4\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42362?source=related_link\">",
"      Enterotoxicity of chemotherapeutic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=related_link\">",
"      Epidemiology and clinical features of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15063?source=related_link\">",
"      Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17400?source=related_link\">",
"      Mohs surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44121?source=related_link\">",
"      Nevoid basal cell carcinoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/26/26018?source=related_link\">",
"      Patient information: Skin cancer (non-melanoma) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18073?source=related_link\">",
"      Primary prevention of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14293?source=related_link\">",
"      Systemic treatment of advanced cutaneous squamous and basal cell carcinomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=related_link\">",
"      Treatment and prognosis of cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=related_link\">",
"      Treatment of basal cell carcinomas at high risk for recurrence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_23_13691="Weaning technique success";
var content_f13_23_13691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rate of successful weaning with various weaning techniques",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Weaning technique",
"       </td>",
"       <td class=\"subtitle1\">",
"        Relative rate of successful",
"weaning (95% confidence interval)",
"       </td>",
"       <td class=\"subtitle1\">",
"        P value",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Once daily trial of spontaneous breathing vs",
"intermittent mandatory ventilation",
"       </td>",
"       <td>",
"        2.83 (1.36-5.89)",
"       </td>",
"       <td>",
"        &lt;0.006",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Once daily trial of spontaneous breathing vs",
"pressure-support ventilation",
"       </td>",
"       <td>",
"        2.05 (1.04-4.04)",
"       </td>",
"       <td>",
"        &lt;0.04",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Once daily trial of spontaneous breathing vs",
"intermittent trials of spontaneous breathing",
"       </td>",
"       <td>",
"        1.24 (0.64-2.41)",
"       </td>",
"       <td>",
"        0.54",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Proportional-hazards regression analysis was used to estimate the 95 percent confidence interval of the relative rate of successful weaning.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Esteban, A, Frutos, F, Tobin, MJ, et al, N Engl J Med 1995; 332:345.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_23_13691=[""].join("\n");
var outline_f13_23_13691=null;
var title_f13_23_13692="Types of allergic reactions";
var content_f13_23_13692=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of allergic reactions (Gell and Coombs)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         I",
"        </p>",
"        <p>",
"         Immediate reaction (30 to 60 min)",
"        </p>",
"        <p>",
"         Accelerated reaction (1 to 72 hours)",
"        </p>",
"       </td>",
"       <td>",
"        Anaphylactic, immediate-type hypersensitivity",
"       </td>",
"       <td>",
"        Antigen exposure causes release of vasoactive substances, such as histamine, prostaglandins, and leukotrienes from mast cells or basophils. This response is usually but not always IgE-dependent.",
"       </td>",
"       <td>",
"        <p>",
"         Anaphylaxis",
"        </p>",
"        <p>",
"         Angioedema",
"        </p>",
"        <p>",
"         Bronchospasm",
"        </p>",
"        <p>",
"         Urticaria (hives)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        Antibody-dependent cytotoxicity",
"       </td>",
"       <td>",
"        An antigen or hapten that is intimately associated with a cell binds to antibody, leading to cell or tissue injury",
"       </td>",
"       <td>",
"        <p>",
"         Hemolytic anemia",
"        </p>",
"        <p>",
"         Interstitial nephritis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        Immune complex disease",
"       </td>",
"       <td>",
"        Damage is caused by formation or deposition of antigen-antibody complexes in vessels or tissue",
"       </td>",
"       <td>",
"        Serum sickness",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        Cell-mediated or delayed hypersensitivity",
"       </td>",
"       <td>",
"        Antigen exposure sensitizes T cells, which then mediate tissue injury",
"       </td>",
"       <td>",
"        Contact dermatitis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         V",
"        </p>",
"        <p>",
"         (&gt;72 hours)",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Uncertain, but probably involving T cell cytotoxicity",
"       </td>",
"       <td>",
"        Maculopapular rash",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Weiss ME, Adkinson NF. Immediate hypersensitivity reactions to penicillin and related antibiotics. Clin Allergy 1988; 18:515.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_23_13692=[""].join("\n");
var outline_f13_23_13692=null;
var title_f13_23_13693="Antiviral Rx HBeAg positive";
var content_f13_23_13693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52919&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52919&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Responses to approved antiviral therapies among treatment-naive patients with HBeAg-positive chronic hepatitis B",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Placebo/control groups from multiple studies, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Standard IFN-&alpha; 5 MU daily or 10 MU three times per week for 12-24 weeks, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Lamivudine 100 mg daily for 48-52 weeks, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Adefovir 10 mg daily for 48 weeks, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Entecavir 0.5 mg daily for 48 weeks, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Tenofovir 300 mg daily for 48 weeks, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Telbivudine 600 mg daily for 52 weeks, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       PegIFN&alpha; 180 mcg once weekly for 48 weeks, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Peg IFN&alpha; 180 mcg once weekly + Lamivudine 100 mg daily for 48 weeks, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Loss of serum HBV DNA*",
"      </td>",
"      <td>",
"       0-17",
"      </td>",
"      <td>",
"       37",
"      </td>",
"      <td>",
"       40-44",
"      </td>",
"      <td>",
"       21",
"      </td>",
"      <td>",
"       67",
"      </td>",
"      <td>",
"       76",
"      </td>",
"      <td>",
"       60",
"      </td>",
"      <td>",
"       25",
"      </td>",
"      <td>",
"       69",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Loss of HBeAg",
"      </td>",
"      <td>",
"       6-12",
"      </td>",
"      <td>",
"       33",
"      </td>",
"      <td>",
"       17-32",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       22",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       26",
"      </td>",
"      <td>",
"       30/34&bull;",
"      </td>",
"      <td>",
"       27/28&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       HBeAg seroconversion",
"      </td>",
"      <td>",
"       4-6",
"      </td>",
"      <td>",
"       Difference of 18",
"      </td>",
"      <td>",
"       16-21",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       21",
"      </td>",
"      <td>",
"       21",
"      </td>",
"      <td>",
"       22",
"      </td>",
"      <td>",
"       27/32&bull;",
"      </td>",
"      <td>",
"       24/27&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Loss of HBsAg",
"      </td>",
"      <td>",
"       0-1",
"      </td>",
"      <td>",
"       7.80",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       3.2",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Normalization of ALT",
"      </td>",
"      <td>",
"       7-24",
"      </td>",
"      <td>",
"       Difference of 23",
"      </td>",
"      <td>",
"       41-75",
"      </td>",
"      <td>",
"       48",
"      </td>",
"      <td>",
"       68",
"      </td>",
"      <td>",
"       68",
"      </td>",
"      <td>",
"       77",
"      </td>",
"      <td>",
"       39",
"      </td>",
"      <td>",
"       46",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Histologic improvement",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       49-56",
"      </td>",
"      <td>",
"       53",
"      </td>",
"      <td>",
"       72",
"      </td>",
"      <td>",
"       74",
"      </td>",
"      <td>",
"       65",
"      </td>",
"      <td>",
"       38&Delta;",
"      </td>",
"      <td>",
"       41&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Durability of response",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       80-90",
"      </td>",
"      <td>",
"       50-80&loz;",
"      </td>",
"      <td>",
"       &sim;90&loz;",
"      </td>",
"      <td>",
"       69&loz;",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       &sim;80",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NA: not available.",
"     <br>",
"      * Hybridization or branched chain DNA assays (lower limit of detection 20,000-200,000 international units/mL or 5-6 log copies/mL) in standard IFN-&alpha; studies and some lamivudine studies, and PCR assays (lower limit of detection approximately 50 international units/mL or 250 copies/mL) in other studies.",
"      <br>",
"       &bull; Responses at week 48/week 72 (24 weeks after stopping treatment).",
"       <br>",
"        &Delta; Post-treatment biopsies obtained at week 72.",
"        <br>",
"         &loz; Lamivudine and entecavir - no or short duration of consolidation treatment, Adefovir and telbivudine - most patients had consolidation treatment.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50:661. Available online at file://publish.aasld.org/Pages/Default.aspx. Accessed September 8th 2009. Copyright &copy; 2009 American Association for the Study of Liver Diseases.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_23_13693=[""].join("\n");
var outline_f13_23_13693=null;
var title_f13_23_13694="Graft versus leukemia in CML";
var content_f13_23_13694=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F75962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F75962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Kinetics of the graft-versus-leukemia effect in chronic myeloid leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 298px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These graphs show the kinetics of attainment of molecular complete remission (CR) in chronic myelogenous leukemia following allogeneic non-myeloablative hematopoietic cell transplantation (HCT). Residual malignant disease was tracked via reverse transcriptase polymerase chain reaction, using the ratio of BCR-ABL to ABL (graph on left). The time course for attainment of donor T-cell chimerism (percent T-cells of donor origin) is shown on the right. One to three months post-HCT, no patient achieved molecular CR (ie, minimal residual disease [MRD] negative status), a time when only two (1 month) or eight (3 months) of 15 patients had achieved full donor T-cell chimerism (ie, 100 percent donor T-cells). At six months, 12 of the 14 tested patients had achieved full donor chimerism, by which time most (8 of the 10 tested) had also achieved molecular CR. These graphs show that attainment of molecular CR following non-myeloablative HCT requires the presence of a graft-versus-leukemia effect, which is not maximally effective until virtually all of the patient's T-cells are of donor origin. This is in contrast to conventional (myeloablative) HCT, following which most patients have 100 percent donor T-cell chimerism and are MRD negative within one to three months of transplantation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Uzunel, M, et al. Blood 2003; 101:469.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_23_13694=[""].join("\n");
var outline_f13_23_13694=null;
var title_f13_23_13695="Proximal humerus fracture-dislocation";
var content_f13_23_13695=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proximal humerus fracture-dislocation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The antero-posterior radiograph above shows a fracture dislocation of the proximal humerus. The glenoid and a large fragment of the greater tuberosity are easily seen adjacent to the humeral head. Fracture dislocations require urgent orthopedic referral.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Robinson CM. Proximal humerus fractures. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_23_13695=[""].join("\n");
var outline_f13_23_13695=null;
